Podcasts about mayo clinic college

Limb-girdle muscular dystrophies (LGMDs) encompass a group of genetically heterogeneous skeletal muscle disorders. There has been an explosion of newly identified LGMD subtypes in the past decade, and results from preclinical studies and early-stage clinical trials of genetic therapies are promising for future disease-specific treatments. In this episode, Gordon Smith, MD, FAAN, speaks with Teerin Liewluck, MD, FAAN, FANA, author of the article “Limb-Girdle Muscular Dystrophies” in the Continuum® October 2025 Muscle and Neuromuscular Junction Disorders issue. Dr. Smith is a Continuum® Audio interviewer and a professor and chair of neurology at Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research at Virginia Commonwealth University in Richmond, Virginia. Dr. Liewluck is a professor of neurology at the Division of Neuromuscular Medicine and Muscle Pathology Laboratory at Mayo Clinic College of Medicine in Rochester, Minnesota. Additional Resources Read the article: Limb-Girdle Muscular Dystrophies Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @gordonsmithMD Guest: @TLiewluck Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Smith: This is Dr Gordon Smith with Continuum Audio. Today I'm interviewing Dr Teerin Liewluck, a good friend of mine at the Mayo Clinic, about his article on the limb girdle muscular dystrophies. This article appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders, a topic that is near and dear to my heart. Teerin, welcome to the podcast, and maybe you can introduce yourself to our listeners. Dr Liewluck: Thank you very much, Gordon, and I want to say hi to all the Continuum fans. So, I'm Dr Teerin Liewluck, I'm the professor of neurology at Mayo Clinic in Rochester, Minnesota. So, my practice focus on all aspects of muscle diseases, both acquired and genetic myopathies. Glad to be here. Dr Smith: I just had the great pleasure of seeing you at a seminar in Houston where you talked about this topic. And so, I'm really primed for this conversation, which I'm very excited about. I find this topic a little hard, and I'm hoping I can learn more from you. And I wonder if, as we get started, recognizing many of our listeners are not in practices focused purely on muscle disease, maybe you can provide some context about why this is important for folks doing general neurology or even general neuromuscular medicine? Why do they need to know about this? Dr Liewluck: Yes, certainly. So, I would say limb girdle muscular dystrophy probably the most complex category of subgroup of muscle diseases because, by itself, it includes thirty-four different subtypes, and the number's still expanding. So, each subtype is very rare. But if you group together, it really have significant number of patients, and these patients present with proximal weakness, very high CK, and these are common patients that can show up in the neurology clinic. So, I think it's very important even for general neurologists to pick up what subtle clues that may lead to the diagnosis because if we are able to provide correct diagnosis for the patients, that's very important for patient management. Dr Smith: So, I wonder if maybe we can talk a little bit about the phenotype, Terran. I mean, your article does a great job of going over the great diversity. And you know, I think many of us here, you know, limb girdle muscular dystrophy and we think of limb girdle weakness, but the phenotypic spectrum is bananas, right? Rhabdomyolysis, limb girdle distal myopathy. I mean, when should our listeners suspect LGMD? Dr Liewluck: Yes, I think by the definition to all the LGMD patients will have limb girdle of proximal weakness and very high CK. So, these are common phenotypes among thirty-four different subtypes. But if it did take into details, they have some subtle differences. In the article, what I try to simplify all these different subtypes that we can categorize at least half of them into three main group that each group the underlying defect sharing among those subtypes and also translate into similar muscles and extra muscular manifestations. You will learn that some of the limb girdle muscular dystrophy may present with rhabdomyolysis. And we typically think of this as metabolic myopathies. But if you have a rhabdomyolysis patient, the CK remain elevated even after the acute episode, that's the key that we need to think this could be LGMD. That's for an example. Dr Smith: So, I wonder if maybe we can start there. I was going to go in a different direction, but this is a good transition. It's easy to see the opportunity to get confused between LGMD or, in that case, a metabolic myopathy or other acquired myopathies. And I think particularly adult neurologists are more accustomed to seeing acquired muscle disease. Are there particular clues that, or pearls that adult neurologists seeing patients with muscle disease can use to recognize when they should be thinking about LGMD given the diverse phenotype? Dr Liewluck: Yes. What I always tell the patient is that there are more than a hundred different types of muscle diseases, but we can easily divide into groups: acquired and genetic or hereditary. So, the acquired disease is when you encounter the patients who present with acute or subacute cause of the weakness, relatively rapidly progressive. But on the opposite, if you encounter the patient who present with a much more slowly progressive cause of weakness over several months or years, you may need to think about genetic disease of the muscle with also including limb-girdle muscular dystrophy. The detailed exam to be able to distinguish between each type of muscular dystrophy. For example, if proximal weakness, certainly limb girdle muscular dystrophy. If a patient has facial weakness, scapular winking, so you would think about facial scapular hematoma dystrophy. So, the slowly progressive cause of weakness, proximal pattern of weakness, CK elevation, should be the point when you think about LGMD. Dr Smith: So, I have a question about diagnostic evaluation. I had a meeting with one of my colleagues, Qihua Fan, who's a great peripheral nerve expert, who also does neuromuscular pathology. And we were talking about how the pathology field has changed so much over the last ten years, and we're doing obviously fewer muscle biopsies. Our way of diagnosing them has changed a lot with the evolution of genetic testing. What's your diagnostic approach? Do you go right to genetic testing? Do you do targeted testing based on phenotype? What words of wisdom do you have there? Dr Liewluck: Yes, so, I mean, being a muscle pathologist myself, it is fair to say that the utility of muscle biopsies when you encounter a patient with suspects that limb girdle muscular dystrophy have reduced over the year. For example, we used to have like fifteen, seventeen hundred muscle biopsies a year; now we do only thirteen hundred biopsies a year. Yes, as you pointed out, the first step in my practice if I suspect LGMD is to go with genetic testing. And I would prefer the last gene panel that not only include the LGMD, but also include all other genetic muscle disease as well as the conjunctive myopic syndrome, because the phenotype can be somehow difficult to distinguish in certain patients. Dr Smith: So, do you ever get a muscle biopsy, Teerin? I mean you obviously do; only thirteen hundred. Holy cow, that's a lot. So, let me reframe my question. When do you get a muscle biopsy in these patients? Dr Liewluck: Muscle biopsy still is present in LGMD patients, it's just we don't use it at the first-tier diagnostic test anymore. So, we typically do it in selected cases after the genetic testing in those that came back inconclusive. As you know, you may run into the variant of unknown significance. You may use the muscle biopsy to see, is there any histopathology or abnormal protein Western blot that may further support the heterogenicity of the VUS. So, we still do it, but it typically comes after genetic testing and only in the selected cases that have inconclusive results or negative genetic testing. Dr Smith: I'd like to ask a question regarding serologic testing for autoantibodies. I refer to a really great case in your article. There are several of them, but this is a patient, a FKRP patient, who was originally thought to have dermatomyositis based on a low-titer ME2 antibody. You guys figured out the correct diagnosis. We send a lot of antibody panels out. Wonder if you have any wisdom, pearls, pitfalls, for how to interpret antibody tests in patients with chronic myopathies? We send a lot of them. And that's the sort of population where we need to be thinking about limb-girdle muscular dystrophies. It's a great case for those, which I hope is everyone who read your article in detail. What do you have to say about that? Dr Liewluck: Yes, so myositis antibodies, we already revolutionized a few of muscle diseases. I recall when I finished my fellowship thirteen years ago, so we don't really have much muscle myositis antibodies to check. But now the panel is expanded. But again, the antibodies alone cannot lead to diagnosis. You need to go back to your clinical. You need to make sure the clinical antibodies findings are matched. For example, if the key that- if the myocytes specific antibodies present only at the low positive title, it's more often to be false positive. So, you need to look carefully back in the patient, the group of phenotypes, and when in doubt we need to do muscle biopsies. Now on the opposite end, the other group of the antibody is the one for necrotizing autoimmune myopathy; or, the other name, immune-mediated necrotizing myopathy. This is the new group that we have learned only just recently that some patients may present as a typical presentation. I mean, when even thinking about the whole testing autoimmune myopathy, we think about those that present with some acute rapidly progressive weakness, maybe has history of sudden exposures. But we have some patients that present with very slowly progressive weakness like muscular dystrophies. So now in my practice, if I encounter a patient I suspect LGMD, in addition to doing genetic testing for LGMD, I also test for necrotizing doing with myopathy antibodies at the same time. And we typically get antibody back within what, a week or two, but projected testing would take a few months. Dr Smith: Yeah. And I guess maybe you could talk a little bit about pitfalls and interpretation of genetic tests, right? I think you have another case in your article, and I've certainly seen this, where a patient is misdiagnosed as having a genetic myopathy, LGMD, based on, let's say, just a misinterpretation of the genetic testing, right? So, I think we need to think of it on both sides. And I like the fact that the clinical aspects of diagnosis really are first and foremost most important. But maybe you can talk about wisdom in terms of interpretation of the genetic panel?  Dr Liewluck:Yes. So genetic testing, I think, is a complex issue, particularly for interpretation. And if you're not familiar with this, it's probably best to have your colleagues in genetics that help looking at this together. So, I think the common scenario we encounter is that in those dystrophies that are autosomal recessive, so we expect that the patient needs to have two abnormal copies of the genes to cause the disease. And if patients have only one abnormal copy, they are just a carrier. And commonly we see patients refer to us as much as dystrophy is by having only one abnormal copy. If they are a carrier, they should not have the weakness from that gene abnormality. So, this would be the principle that we really need to adhere. And if you run into those cases, then maybe you need to broaden your differential diagnosis. Dr Smith: I want to go back to the clinical phenomenology, and I've got a admission to make to you, Teerin. And I find it really hard to keep track of these disorders at, you know, thirty-four and climbing a lot of overlap, and it's hard to remember them. And I'm glad that I'm now going to have a Continuum article I can go to and look at the really great tables to sort things out. I'm curious whether you have all these top of mind? Do you have to look at the table too? And how should people who are seeing these patients organize their thoughts about it? I mean, is it important that you memorize all thirty-four plus disorders? How can you group them? What's your overall approach to that? Dr Liewluck: I need to admit that I've not memorize all twenty-four different subtypes, but I think what I triy to do even in my real-life practice is group it all together if you can. For example, I think that the biggest group of these LGMD is what we call alpha-dystroglycanopathies. So, this include already ten different subtypes of recessive LGMD. So alpha-dystroglycan is the core of the dystrophin-associated glycoprotein complex. And it's heavy glycosylated protein. So, the effect in ten different genes can affect the glycosylation or the process of adding sugar chain to this alpha-dystroglycan. And they have similar features in terms of the phenotype. They present with proximal weakness, calf pseudohypertrophy, very high CK, some may have recurrent rhabdomyolysis, and cardiac and rhythmic involvement are very common. This is one major group. Now the second group is the limb-girdle muscular dystrophy due to defective membrane repair, which includes two subtypes is the different and on dopamine five. The common feature in this group is that the weakness can be asymmetric and despite proximal weakness, they can have calf atrophy. On muscle biopsy sometimes you can see a myeloid on the muscle tissues. And the third group is the sarcoglycanopathy, which includes four different subtypes, and the presentation can look like we share. For the rest, sometimes go back to the table. Dr Smith: Thank you for that. And it prompts another question that I always wonder about. Do you have any theories about why such variability in the muscle groups that are involved? I mean, you just brought up dystroglycanopathy, for instance, as something that can cause a very distal predominant myopathy; others do not. Do we at this point now have an understanding given the better genetics that we have on this and work going on in therapeutic development, which I want to get to in a minute, that provides any insight why certain muscle groups are more affected? Dr Liewluck: Very good question, Gordon. And I would say the first question that led me interested in muscle disease---and this happened probably back in 2000 when I just finished medical school---is why, why, why? Why does muscle disease tend to affect proximal muscles? I thought by now, twenty-five years later, we'd have the answer. I don't. I think this, you don't know clearly why muscle diseases, some affect proximal, some affect distal. But the hypothesis is, and probably my personal hypothesis is, that maybe certain proteins may express more in certain muscles and that may affect different phenotypes. But, I mean, dysferlin has very good examples that can confuse us because some patients present with distal weakness, some patients present with proximal weakness, that's by the same gene defect. And in this patient, when we look at the MRI in detail, actually the patterns of fatty replacements in muscle are the same. Even patient who present clinically as a proximal or distal weakness, the imaging studies show the same finding. Bottom line, we don't know. Dr Smith: Yeah, who knew it could be so complex? Teerin, you brought up a really great point that I wanted to ask about, which is muscle MRI scan, right? We're now seeing studies that are doing very broad MR imaging. Do you use some muscle MRI very frequently in your clinical evaluation of these patients? And if so, how? Dr Liewluck: Maybe I don't use it as much as I could, but the most common scenario I use in this setting is when I have the genetic testing come back with the VUS. So, we look at each VUS, each gene in detail. And if anything is suspicious, what I do typically go back to the literature to see if that gene defect in particular has any common pattern of muscle involvement on the MRI. And if there is, I use MRI as one of the two to try to see if I can escalate the pathogenicity of that VUS. Dr Smith: And a VUS is a “Variant of Unknown Significance,” for our listeners. I'm proud that I remember that as a geneticist. These are exciting times in neurology in general, but particularly in an inherited muscle disease. And we're seeing a lot of therapeutic development, a lot going on in Duchenne now. What's the latest in terms of disease-modifying therapeutics and gene therapies in LGMD? Dr Liewluck: Yes. So, there are several precritical and early-phase critical trials for gene therapy for the common lymphoma of muscular dystrophies. For example, the sarcoglycanopathies, and they also have some biochemical therapy that arepossible for the LGMD to FKRP. But there are many things that I expect probably will come into the picture broader or later phase of critical tryouts, and hopefully we have something to offer for the patients similar to patients with Duchenne muscular dystrophy. Dr Smith: What haven't we talked about, I mean, holy cow? There's so much in your article. What's one thing we haven't talked about that our listeners need to hear? Dr Liewluck: Good questions. So, I think we covered all, but often we get patients with proximal weakness and high CK, and they all got labeled as having limb-girdlemuscular dystrophy. What I want to stress is that proximal weakness and high CK is a common feature for muscle diseases, so they need to think broad, need to think about all possibilities. Particularly don't want to miss something treatable. Chronic, slowly progressive cause, as I mentioned earlier, we think more about muscle dystrophy, but at the cranial range, we know that rare patients with necrotic autonomyopathy and present with limb good of weakness at a slowly progressive cost. So, make sure you think about these two when suspecting that LGMD patient diabetic testing has come back inconclusive. Dr Smith: Well, that's very helpful. And fortunately, there's several other articles in this issue of Continuum that help people think through this issue more broadly. Teerin, you certainly don't disappoint. I enjoyed listening to you about a month ago, and I enjoyed reading your article a great deal and enjoy talking to you even more. Thank you very much. Dr Liewluck: Thank you very much, Gordon. Dr Smith: Again, today I've been interviewing Dr Teerin Liewluck about his article on limb-girdle muscular dystrophy, which appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Please be sure to check out Continuum Audio episodes for this and other issues. And thanks to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

While genetic testing has replaced muscle biopsy in the diagnosis of many genetic myopathies, clinical assessment and the integration of clinical and laboratory findings remain key elements for the diagnosis and treatment of muscle diseases. In this episode, Casey Albin, MD, speaks with Margherita Milone, MD, PhD, FAAN, FANA, author of the article “A Pattern Recognition Approach to Myopathy” in the Continuum® October 2025 Muscle and Neuromuscular Junction Disorders issue. Dr. Albin is a Continuum® Audio interviewer, associate editor of media engagement, and an assistant professor of neurology and neurosurgery at Emory University School of Medicine in Atlanta, Georgia. Dr. Milone is a professor of neurology and the director of the Muscle Pathology Laboratory at Mayo Clinic College of Medicine and Science in Rochester, Minnesota. Additional Resources Read the article: A Pattern Recognition Approach to Myopathy Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @caseyalbin Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Albin: Hello, this is Dr Casey Albin. Today I'm interviewing Dr Margherita Milone on her article on a pattern recognition approach to myopathy, which appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Welcome to the podcast, Dr Milone. Thank you so much for joining us. I'll start off by having you introduce yourself to our listeners. Dr Milone: Hello Casey, thank you so much for this interview and for bringing the attention to the article on muscle diseases. So, I'm Margherita Milone. I'm one of the neuromuscular neurologists at Mayo Clinic in Rochester. I have been interested in muscle disorders since I was a neurology resident many years ago. Muscle diseases are the focus of my clinical practice and research interest. Dr Albin: Wonderful. Thank you so much. When I think about myopathies, I generally tend to think of three large buckets: the genetic myopathy, the inflammatory myopathies, and then the necrotizing myopathies. Is that a reasonable approach to conceptualizing these myopathies? Dr Milone: Yeah, the ideology of the myopathies can be quite broad. And yes, we have a large group of genetic muscle diseases, which are the most common. And then we have immune-mediated muscle diseases, which include inflammatory myopathies as well as some form of necrotizing myopathies. Then we have some metabolic myopathies, which could be acquired or could be genetic. And then there are muscle diseases that are due to toxins as well as to infection. Dr Albin: Wow. So, lots of different etiologies. And that really struck me about your article, is that these can present in really heterogeneous ways, and some of them don't really read the rule book. So, we have to have a really high level of suspicion, for someone who's coming in with weakness, to remember to think about a myopathy. One of the things that I like to do is try to take us through a little bit of a case to sort of walk us through how you would approach if someone comes in. So, let's say you get, you know, a forty-year-old woman, and she's presenting with several months of progressive weakness. And she says that even recently she's noted just a little bit of difficulty swallowing. It feels to her like things are getting stuck. What are some of the things when you are approaching the history that would help you tease this to a myopathy instead of so many other things that can cause a patient to be weak? Dr Milone: Yes. So, as you mentioned, people who have a muscle disease have the muscle weakness often, but the muscle weakness is not just specific for a muscle disease. Because you can have a mass weakness in somebody who has a neurogenic paralysis. The problem with diagnosis of muscle diseases is that patients with these disorders have a limited number of symptom and sign that does not match the large heterogeneity of the etiology. So, in someone who has weakness, that weakness could represent a muscle disease, could represent an anterior horn cell disease, could represent a defect of neuromuscular junction. The clinical history of weakness is not sufficient by itself to make you think about a muscle disease. You have to keep that in the differential diagnosis. But your examination will help in corroborating your suspicion of a muscle disease. Let's say if you have a patient, the patient that you described, with six months' history of progressive weakness, dysphagia, and that patient has normal reflexes, and the patient has no clinical evidence for muscle fatigability and no sensory loss, then the probability that that patient has a myopathy increases. Dr Albin: Ah, that's really helpful. I'm hearing a lot of it is actually the lack of other findings. In some ways it's asking, you know, have you experienced numbness and tingling? And if not, that's sort of eliminating that this might not be a neuropathy problem. And then again, that fatigability- obviously fatigability is not specific to a neuromuscular junction, but knowing that is a hallmark of myasthenia, the most common of neuromuscular disorders. Getting that off the table helps you say, okay, well, it's not a neuromuscular junction problem, perhaps. Now we have to think more about, is this a muscle problem itself? Are there any patterns that the patients describe? I have difficulty getting up from a chair, or I have difficulty brushing my hair. When I think of myopathies, I historically have thought of, sort of, more proximal weakness. Is that always true, or not so much? Dr Milone: Yeah. So, there are muscle diseases that involve predominantly proximal weakness. For example, the patient you mentioned earlier could have, for example, an autoimmune muscle disease, a necrotizing autoimmune myopathy; could have, perhaps, dermatomyositis if there are skin changes. But a patient with muscle disease can also present with a different pattern of weakness. So, myopathies can lead to this weakness, and foot drop myopathies can cause- can manifest with the weakness of the calf muscles. So, you may have a patient presenting to the clinic who has no the inability to stand on tiptoes, or you may have a patient who has just facial weakness, who has noted the difficulty sealing their lips on the glasses when they drink and experiencing some drooling in that setting, plus some hand weakness. So, the muscle involved in muscle diseases can vary depending on the underlying cause of the muscle disease. Dr Albin: That's really helpful. So, it really is really keeping an open mind and looking for some supporting features, whether it's bulbar involvement, extraocular eye muscle involvement; looking, you know, is it proximal, is it distal? And then remembering that any of those patterns can also be a muscle problem, even if sometimes we think of distal being more neuropathy and proximal myopathy. Really, there's a host of ranges for this. I really took that away from your article. This is, unfortunately, not just a neat way to box these. We really have to have that broad differential. Let me ask another question about your history. How often do you find that patients complain of, sort of, muscular cramping or muscle pain? And does that help you in terms of deciding what type of myopathy they may have? Dr Milone: Many patients with muscle disease have muscle pain. The muscle pain could signal a presence of inflammation in skeletal muscle, could be the result of overuse from a muscle that is not functioning normally. People who have myotonia experience muscle stiffness and muscle pain. Patients who have a metabolic myopathy usually have exercise-induced muscle pain. But, as we know, muscle pain is also very nonspecific, so we have to try to find out from the patient in what setting the pain specifically occurs. Dr Albin: That's really helpful. So, it's asking a little bit more details about the type of cramping that they have, the type of pain they may be experiencing, to help you refine that differential. Similarly, one of the things that I historically have always associated with myopathies is an elevation in the CK, or the creatinine kinase. How sensitive and specific is that, and how do you as the expert sort of take into account, you know, what their CK may be? Dr Milone: So, this is a very good point. And the elevation of creatine kinase can provide a clue that the patient has a muscle disease, but it is nonspecific for muscle disease because we know that elevation of creatine kinase can occur in the setting of a neurogenic process. For example, we can see elevation of the creatine kinase in patients who have ALS or in patients who have spinal muscular atrophy. And in these patients---for example, those with spinal muscular atrophy---the CK elevation can be also of significantly elevated up to a couple of thousand. Conversely, we can have muscle diseases where the CK elevation does not occur. Examples of these are some genetic muscle disease, but also some acquired muscle diseases. If we think of, for example, cases where inflammation in the muscle occurs in between muscle fibers, more in the interstitium of the muscle, that disease may not lead to significant elevation of the CK. Dr Albin: That's super helpful. So, I'm hearing you say CK may be helpful, but it's neither completely sensitive nor completely specific when we're thinking about myopathic disorders. Dr Milone: You are correct. Dr Albin: Great. So, coming back to our patients, you know, she says that she has this dysphasia. How do bulbar involvement or extraocular eye movement involvement, how do those help narrow your differential? And what sort of disorders are you thinking of for patients who may have that bulbar or extraocular muscle involvement? Dr Milone: Regarding dysphagia, that can occur in the setting of acquired myopathies relatively frequent; for example, in inclusion body myositis or in other forms of inflammatory myopathy. Your patient, I believe, was in their forties, so it's a little bit too young for inclusion body myositis. Involvement of the extraocular muscles is usually much more common in genetic muscle diseases and much less frequent in hereditary muscle disease. So, if there is involvement of the extraocular muscles, and if there is a dysphagia, and if there is a proximal weakness, you may think about oculopharyngeal muscular dystrophy, for example. But obviously, in a patient who has only six months of history, we have to pay attention of the degree of weakness the patient has developed since the symptom onset. Because if the degree of weakness is mild, yes, it could still be a genetic or could be an acquired disease. But if we have a patient who, in six months, from being normal became unable to climb stairs, then we worry much more about an acquired muscle disease. Dr Albin: That's really helpful. So, the time force of this is really important. And when you're trying to think about, do I put this in sort of a hereditary form of muscle disease, thinking more of an indolent core, something that's going to be slowly progressive versus one of those inflammatory or necrotizing pathologies, that's going to be a much more quick onset, rapidly progressive, Do I have that right? Dr Milone: In general, the statement is correct. They tend, acquired muscle disease, to have a faster course compared to a muscular dystrophy. But there are exceptions. There have been patients with immune mediated necrotizing myopathy who have been misdiagnosed as having limb-girdle muscular dystrophy just because the disease has been very slowly progressive, and vice versa. There may be some genetic muscle diseases that can present in a relatively fast way. And one of these is a lipid storage myopathy, where some patients may develop subacutely weakness, dysphagia, and even respiratory difficulties. Dr Albin: Again, I'm hearing you say that we really have to have an open mind that myopathies can present in a whole bunch of different ways with a bunch of different phenotypes. And so, keeping that in mind, once you suspect someone has a myopathy, looking at the testing from the EMG perspective and then maybe laboratory testing, how do you use that information to guide your work up? Dr Milone: The EMG has a crucial role in the diagnosis of muscle diseases. Because, as we said earlier, weakness could be the result of muscle disease or other form of neuromuscular disease. If the EMG study will show evidence of muscle disease supporting your diagnostic hypothesis, now you have to decide, is this an acquired muscle disease or is this a genetic muscle disease? If you think that, based on clinical history of, perhaps, subacute pores, it is more likely that the patient has an acquired muscle disease, then I would request a muscle biopsy. The muscle biopsy will look for structural abnormalities that could help in narrowing down the type of muscle disease that the patient has. Dr Albin: That's really helpful. When we're sending people to get muscle biopsies, are there any tips that you would give the listeners in terms of what site to biopsy or what site, maybe, not to biopsy? Dr Milone: This is a very important point. A muscle biopsy has the highest diagnostic yield if it's done in a muscle that is weak. And because muscle diseases can result in proximal or distal weakness, if your patient has distal weakness, you should really biopsy a distal muscle. However, we do not wish to biopsy a muscle that is too weak, because otherwise the biopsy sample will result just in fibrous and fatty connected tissue. So, we want to biopsy a muscle that has mild to moderate weakness. Dr Albin: Great. So, a little Goldilocks phenomenon: has to be some weak, but not too weak. You got to get just the right feature there. I love that. That's a really good pearl for our listeners to take. What about on the flip side? Let's say you don't think it's an acquired a muscular disease. How are you handling testing in that situation? Dr Milone: If you think the patient has a genetic muscle disease, you pay a lot of attention to the distribution of the weakness. Ask yourself, what is the best pattern that represent the patient's weakness? So, if I have a patient who has facial weakness, dysphagia, muscle cramping, and then on examination represent myotonia, then at that point we can go straight to a genetic test for myotonic dystrophy type one. Dr Albin: That's super helpful. Dr Milone: So, you request directly that generic test and wait for the result. If positive, you will have proof that your diagnostic hypothesis was correct. Dr Albin: You're using the genetic testing to confirm your hypothesis, not just sending a whole panel of them. You're really informing that testing based on the patient's pattern of weakness and the exam findings, and sometimes even the EMG findings as well. Is that correct? Dr Milone: You are correct, and ideally, yes. And this is true for certain muscle diseases. In addition to myotonic dystrophy type one, for example, if you have a patient who has fascial scapulohumeral muscular weakness, you can directly request a test for FSHD. So, the characterization of the clinical phenotype is crucial before selecting the genetic test for diagnosis. Dr Albin: Wonderful. Dr Milone: However, this is not always possible, because you may have a patient who has just a limb-girdle weakness, and the limb-girdle weakness can be limb-girdle muscular dystrophy. But we know that there are many, many types of limb-girdle muscular dystrophies. Therefore, the phenotype is not sufficient to request specific genetic tests for one specific form of a limb-girdle muscular dystrophy. And in those cases, more complex next-generation sequencing panels have a higher chance of providing the answer. Dr Albin: Got it, that makes sense. So, sometimes we're using a specific genetic test; sometimes, it is unfortunate that we just cannot narrow down to one disease that we might be looking for, and we may need a panel in that situation. Dr Milone: You are correct. Dr Albin: Fantastic. Well, as we wrap up, is there anything on the horizon for muscular disorders that you're really excited about? Dr Milone: Yes, there are a lot of exciting studies ongoing for gene therapy, gene editing. So, these studies are very promising for the treatment of genetic muscle disease, and I'm sure there will be therapists that will improve the patient's quality of life and the disease outcome. Dr Albin: It's really exciting. Well, thank you again. Today I've been interviewing Dr Margarita Malone on her article on a pattern recognition approach to myopathy, which appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Be sure to check out Continuum Audio episodes from this and other issues, and thank you to our listeners for joining us today. And thank you, Dr Milone. Dr Milone: Thank you, Casey. Very nice chatting with you about this. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

On this episode Lara and Vyanka talk to Dr Eoin Flanagan from the Mayo Clinic College of Medicine in Rochester all about how to diagnose and treat autoimmune encephalitis. This is ImmunoTea: Your Immunology Podcast, presented by Dr Lara Dungan and Dr Vyanka Redenbaugh. This is the show where we tell you all about the most exciting research going on in the world of immunology. So grab a cup of tea, sit down and relax and we'll fill you in. Contact us at ImmunoTeaPodcast@gmail.com or @ImmunoTea on twitter. Hosted on Acast. See acast.com/privacy for more information.

On this episode of the AMSSM Sports Medcast, host Dr. Devin McFadden, MD, is joined by Dr. Irfan Asif, MD, FAMSSM, and Dr. Jonathan Finnoff, DO, FAMSSM, to discuss the multi-faceted topic of Paralympic Sports Medicine. In this conversation, Dr. Asif and Dr. Finnoff discuss the following: How they first got involved in USOPC and Paralympic team sports The number of sports in Paralympic competition and the athlete classifications that aim to level the playing field for athletes of different abilities What it's like to take care of Paralympic athletes and their unique requirements The planning process for delivering medical services for Team USA during the Paralympic Games Current and future research efforts regarding Paralympic athletes Overcoming the perceived barriers to entry when providing care for Paralympic athletes and ways to get more involved Dr. Asif is the associate dean for primary care and rural health and professor and chair of the Department of Family and Community at the University of Alabama at Birmingham (UAB). He currently serves as the 2nd Vice President for AMSSM and is an Associate Editor for both the British Journal of Sports Medicine and Sports Health: A Multi-Disciplinary Approach. Dr. Finnoff is the Chief Medical Officer for the United States Olympic and Paralympic Committee, a Clinical Professor in the Department of Physical Medicine and Rehabilitation, University of Colorado, and a Professor in the Department of Physical Medicine and Rehabilitation at Mayo Clinic College of Medicine and Science. He currently serves as the 1st Vice President for AMSSM. Resources: 2025 USOPC Paralympic Sports Medicine Conference https://www.usopc.org/2025-paralympic-sports-medicine-conference PARA-Wise Registry Screening Survey: https://redcap.link/PARAWISE

On this episode of the AMSSM Sports Medcast, host Dr. Devin McFadden, MD, is joined by Dr. Irfan Asif, MD, FAMSSM, and Dr. Jonathan Finnoff, DO, FAMSSM, to discuss the multi-faceted topic of Paralympic Sports Medicine. In this conversation, Dr. Asif and Dr. Finnoff discuss the following: How they first got involved in USOPC and Paralympic team sports The number of sports in Paralympic competition and the athlete classifications that aim to level the playing field for athletes of different abilities What it's like to take care of Paralympic athletes and their unique requirements The planning process for delivering medical services for Team USA during the Paralympic Games Current and future research efforts regarding Paralympic athletes Overcoming the perceived barriers to entry when providing care for Paralympic athletes and ways to get more involved Dr. Asif is the associate dean for primary care and rural health and professor and chair of the Department of Family and Community at the University of Alabama at Birmingham (UAB). He currently serves as the 2nd Vice President for AMSSM and is an Associate Editor for both the British Journal of Sports Medicine and Sports Health: A Multi-Disciplinary Approach. Dr. Finnoff is the Chief Medical Officer for the United States Olympic and Paralympic Committee, a Clinical Professor in the Department of Physical Medicine and Rehabilitation, University of Colorado, and a Professor in the Department of Physical Medicine and Rehabilitation at Mayo Clinic College of Medicine and Science. He currently serves as the 1st Vice President for AMSSM. Resources: 2025 USOPC Paralympic Sports Medicine Conference https://www.usopc.org/2025-paralympic-sports-medicine-conference PARA-Wise Registry Screening Survey: https://redcap.link/PARAWISE

In this episode of "Research Ethics Reimagined," we explore community-engaged research and its role in advancing health equity, particularly in cancer care. Our guest is Monica L. Albertie, Director of Research Operations for Community Outreach and Engagement at the Mayo Clinic Comprehensive Cancer Center. She provides operational leadership for cancer-focused community outreach and community-engaged research aimed at reducing the cancer burden. In addition to her leadership role, Monica also serves as an Assistant Professor of Health Care Administration at the Mayo Clinic College of Medicine and Science. 

In this bonus episode of Problem Solved: The IISE Podcast, we present Dr. Venkatesh Bellamkonda's keynote address from the Healthcare Systems Process Improvement Conference 2025 in Atlanta. As an assistant professor of emergency medicine at the Mayo Clinic College of Medicine and a consultant physician in the Department of Emergency Medicine at Mayo Clinic in Rochester, Minnesota, Dr. Bellamkonda shares his journey into process improvement, inspired by personal experiences and colleagues. He illustrates how quality improvement tools can be applied to everyday challenges, such as organizing a nursery and managing emails.Dr. Bellamkonda also emphasizes the importance of engaging healthcare professionals at all levels through relatable examples and structured training programs. He advocates for using these skills to address significant issues like workplace violence and second victim syndrome, aligning improvement efforts with the core mission of healthcare institutions and the well-being of their teams.Learn more about the HSPI conference at: iise.org/HSPI

Following the 2024 Marginal Zone Lymphoma (MZL) Workshop, CancerNetwork® spoke with multiple attending clinicians about insights they shared regarding the disease state, covering the significance of the workshop and its contribution to advancing research in areas such as prognostic factors and managing adverse events (AEs) related to the disease. Thomas Habermann, MD, professor of Medicine at the Mayo Clinic in Rochester, Minnesota, member of the Lymphoma Research Foundation's Scientific Advisory Board, and MZL Workshop co-chair, spoke about the significance of the MZL Workshop. He highlighted the complexity of these types of diseases, which he believed warranted the establishment of the group. According to Habermann, MZL is a “heterogenous group of disorders” that most contemporaries in the field “don't quite appreciate.” Next, Julie M. Vose, MD, MBA, George and Peggy Payne chair in oncology and chief of Hematology and Oncology at the University of Nebraska Medical Center, and co-editor-in-chief of ONCOLOGY®, spoke about how the MZL Workshop contributes to advancing research and improving outcomes for patients with MZL. She emphasized a need to be more inclusive when enrolling patients with MZL in clinical trials. Then, James R. Cerhan, MD, PhD, professor of Epidemiology at the Mayo Clinic College of Medicine and Science, and Ralph S. and Beverly Caulkins Professor of Cancer Research, spoke about addressing research questions in MZL epidemiology to further disease understanding. He emphasized a need to further study newly identified risk factors of the disease, as well as identifying new treatment targets for patients with MZL. Additionally, Alexandar Tzankov, MD, surgical pathologist and head of the Department of Histopathology and Autopsy at the Institute of Medical Genetics and Pathology at University Hospital Basel, and chair for the European Bone Marrow Working Group, discussed how prognostic factors for MZL may influence treatment. He described how the limited number of studies done with relatively small subsets of patients makes prognoses challenging, as prognostic factors have not been sufficiently explored. Finally, Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, outlined challenges related to AE management of treatments for MZL. He emphasized that safety management practices for MZL are comparable with other B-cell lymphomas, suggesting that use of bridging therapy for CAR T cells and step-up dosing for bispecific antibodies may help with mitigating AEs.

In this episode, Dr. Prathibha Varkey, President of Mayo Clinic Health System & Professor of Medicine and Preventive Medicine, Mayo Clinic College of Medicine and Science, discusses the organization's focus on integration, patient experience, and leveraging AI to revolutionize healthcare. From workforce expansion to cutting-edge technologies for early disease detection, she shares key accomplishments and strategic goals for 2025.

The STFM Podcast is pleased to introduce our new hosts for the 2025 season. Please join us in welcoming Omari A. Hodge, MD, and Jay-Sheree Allen Akambase, MD. Both hosts were instrumental in the success of STFM's Underrepresented in Medicine Initiative. Dr Hodge served as co-host of the URM JAM Podcast, and Dr Allen Akambase developed a webinar series with the Scholarship Work Group. To get things started, our hosts interview each other, discussing how they balance family dynamics, professional goals, and individual aspirations throughout their journey in academic family medicine.  Hosted by Omari A. Hodge, MD, and Jay-Sheree Allen Akambase, MDCopyright © Society of Teachers of Family Medicine, 20245Resources:The URM JAM Podcast - hosted by Tochi Iroku-Malize, MD, MBA, and Omari A. Hodge, MD, and published by STFMURM Scholarship Webinar SeriesMillennial Health hosted by Dr Jay-Sheree AllenOmari A. Hodge, MD Omari A. Hodge, MD, earned his medical degree at Morehouse School of Medicine in Atlanta and completed his family medicine residency at Self Regional Hospital in Greenwood, South Carolina. As a primary care physician, Dr. Hodge has worked in a variety of roles, including campus medicine, urgent care, hospital medicine, and graduate medical education. Previously he served as associate program director with North Georgia Health System in Gainesville, Georgia. Currently Dr Hodge serves as the Founding Program Director for AdventHealth Family Medicine Residency Program at Wesley Chapel in Tampa, Florida, with a mission to equip, educate, and encourage residents to use their God given talents in service to the community. He has also worked at Clarkston Refugee Clinic, underscoring his philosophy of using the gift of medicine to serve others. Dr. Hodge serves on the board of trustees at Christian Medical & Dental Associations. He and his wife Kiera participate in both local and global medical aid relief trips. Additionally, Dr Hodge is a proud father to his four children.Jay-Sheree Allen Akambase, MDJay-Sheree Allen Akambase, MD, is a Preventive Medicine Fellow in the Division of Public Health, Infectious Diseases, and Occupational Medicine at the Mayo Clinic in Rochester also pursuing an Executive master's degree in public health practice at the University of Minnesota. She holds the rank of Assistant Professor of Family Medicine with the Mayo Clinic College of Medicine and previously served as a Senior Associate Consultant and Diversity Leader in the Mayo Clinic Department of Family Medicine in Rochester. In that role she created the first department wide equity, inclusion, and diversity committee to lead the team through the department's 2022-23 EID priorities including a faculty development program to promote leadership among women and underrepresented minorities in Family Medicine. She is the President of the American Academy of Family Physicians Foundation Board of Trustees and is slated to serve as the Foundation's President in 2025. She previously chaired the workgroup responsible for the foundation's humanitarian programs: Family Medicine Cares USA and Family Medicine Cares International where she has been instrumental in relaunching the global health program focused on equity. Recognizing the power of media to deliver relevant and timely health messages, she has contributed to multiple health news and education outlets including ABC News Health, Minnesota Public Radio, Wall Street Journal and the Primary Care Reviews and Perspectives Podcast. You can find her on twitter and Instagram @drjaysheree Link: 

A super informative and interesting interview with Dr. Prathibha Varkey, the President of the Mayo Clinic Health System. Dr. Varkey leads over 17,000 employees serving 16 community hospitals and 50 multispecialty clinics across 39 communities in Minnesota and Wisconsin. Dr. Varkey is a Professor of Medicine and Preventive Medicine at Mayo Clinic College of Medicine and Science.

In this episode we discuss the recent National Society of Genetic Counselor's Practice Resource on Dystrophinopathies, which was recently published in JoGC, with two of the publications' authors. You can find the Journal of Genetic Counseling webpage via onlinelibrary.wiley.com or via the National Society of Genetic Counselors website.   Segment 1: “Genetic counseling for the dystrophinopathies- Practice resource of the National Society of Genetic Counselors”   Ann Martin, MS, CGC is a board certified genetic counselor with Parent Project Muscular Dystrophy (PPMD). Ann serves as the VP of Community Research and Genetic Services and manages a team of genetic counselors who coordinate all aspects of The Duchenne Registry and the Decode Duchenne genetic testing program. Since joining PPMD in 2011, Ann has been directly involved in all aspects of the Registry programs including collection and curation of the Registry data, clinical trial and research study recruitment, data exports, patient and family inquiries, genetic testing, and educational content on the PPMD websites. Ann represents The Duchenne Registry on TREAT-NMD's Global Data Oversight Committee, which is responsible for reviewing requests for data from the TREAT-NMD Global Registries, and serves as the DMD Subgroup Co-Lead. In addition, Ann has been a member of Sarepta Therapeutics' Advisory Board for Early Diagnosis of Duchenne since 2022. Ann is continually engaging and educating both the patient and professional community about the Registry and Duchenne and Becker research. Before joining PPMD, Ann worked as a clinical genetic counselor for 15 years at Carolinas Medical Center in Charlotte, NC, where she provided genetic counseling for pediatric and adult patients with a wide range of genetic disorders. Ann is a graduate of the University of Cincinnati Genetic Counseling Graduate Program. She is board-certified by the American Board of Genetic Counseling and is a member of the National Society of Genetic Counselors. Angela Pickart (she/her) is a licensed, certified genetic counselor practicing in the Genomics Laboratory at Mayo Clinic, performing variant interpretation, report writing and test development for neurogenetics assays. She received her Master of Science degree in Genetic Counseling at the University of Minnesota and has extensive clinical experience in pediatric, neurology, and oncology genetic counseling prior to transitioning to her laboratory role. She has been awarded the academic rank of Assistant Professor of Laboratory Medicine at the Mayo Clinic College of Medicine and Science where she serves as course co-director of the Center for Clinical and Translational Sciences Molecular Variant Evaluation Course. She is also the course co-director of the Laboratory Practicum for the Medical College of Wisconsin Master of Science Genetic Counseling Graduate Program and Adjunct Assistant Professor of the Medical College of Wisconsin School of Graduate Studies.   In this segment we discuss: - Origins and significance of the genetic counseling-specific practice resource for dystrophinopathies. - Changes in the treatment landscape due to FDA-approved therapeutics and ongoing clinical trials for dystrophinopathies. - Strategies for educating patients and families about the implications of genetic testing and diagnosis in dystrophinopathies. - Advocacy roles of genetic counselors in helping patients access the latest therapies and participate in clinical trials for DMD/BMD. - Importance of interdisciplinary collaboration in managing dystrophinopathies and the roles genetic counselors play within these teams. - Potential broader impact of the practice resource on the medical field and patient community.    Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors. Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.  For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.  Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.  DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Sydney Arlen.

Although Alzheimer disease (AD) is the most common neurodegenerative cause of dementia, other etiologies can mimic the typical amnestic-predominant syndrome and medial temporal brain involvement. Neurologists should recognize potential mimics of AD for clinical decision-making and patient counseling. In this episode, Kait Nevel, MD, speaks with Vijay K. Ramanan, MD, PhD, an author of the article “LATE, Hippocampal Sclerosis, and Primary Age-related Tauopathy,” in the Continuum December 2024 Dementia issue. Dr. Nevel is a Continuum® Audio interviewer and a neurologist and neuro-oncologist at Indiana University School of Medicine in Indianapolis, Indiana. Dr. Ramanan is a consultant and assistant professor of neurology in the Division of Behavioral Neurology at Mayo Clinic College of Medicine and Science in Rochester, Minnesota. Additional Resources Read the article: LATE, Hippocampal Sclerosis, and Primary Age-related Tauopathy Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: IUneurodocmom Guest: @vijaykramanan Full episode transcript available here Dr Jones: This is Dr Lyle Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum 's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum Journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Nevel: This is Dr Kait Nevel. Today I'm interviewing Dr Vijay Ramanan about his article he wrote with Dr Jonathan Graff-Radford on LATE hippocampal sclerosis and primary age-related tauopathy, which appears in the December 2024 Continuum issue on dementia. Welcome to the podcast. Vijay, can you please introduce yourself to the audience? Dr Ramanan: Thanks so much, Kait. I'm delighted to be here. So, I am a cognitive neurologist and neuroscientist at the Mayo Clinic in Rochester, Minnesota. I have roles in practice, education and research, but amongst those I see patients with cognitive disorders in the clinic. I help direct our Alzheimer's disease treatment clinic and also do research, including clinical trial involvement and some observational research on genetics and biomarkers related to Alzheimer's and similar disorders. Dr Nevel: Great, thanks for that. So, I'd like to start off by talking about why is LATE hippocampal sclerosis, why is this important for the neurologist practicing in clinic to know about these things? Dr Ramanan: That's a great question. So, if we take a step back, we know that degenerative diseases of the brain are really, really common, and they get more and more common as we get older. I think all neurologists, and in fact most clinicians and large swaths of the general public, are well aware of Alzheimer's disease, which is the most common degenerative cause of cognitive impairment in the population. But there are non-Alzheimer's degenerative diseases which can produce cognitive difficulties as well. And it's important to be aware of those disorders, of their specific presentations and their implications, in part because it's always a healthy thing when we can be as precise and confident about diagnosis and expectation with our patients as possible. I'll look to the analogy of a patient presenting with a myelopathy. As neurologists, we would all find it critical to clarify, is that myelopathy the result of a compressive spondylotic change? The result of an inflammatory disorder, of a neoplastic disorder, of an infectious disorder? It's critical to guide the patient and choose appropriate management options based on the cause of their syndrome. It would potentially harm the patient if you treated an infectious myelopathy with steroids or other immune-suppressant drugs. So, a similar principle holds in cognitive neurology. I accept with humility that we can never be 100% crystal clear certain about things in medicine, just because when you think you got it all figured out there's a curveball. But I want to get as close to that 100% as possible. And recognizing that disorders like LATE or PART can mimic the symptoms, sometimes even the imaging features of Alzheimer's disease. I think it's critical to have heightened awareness of those disorders, how they look, to be able to apply appropriate counseling and management options to patients. I think this becomes particularly critical as we move into an era of disease-specific, and sometimes disease-modifying, therapies, where applying a choice of a treatment option could have significant consequences to a patient if the thing you're treating isn't the thing that the drug is trying to accomplish. So, having awareness and spreading awareness about some of these non-AD causes of cognitive difficulty, I think, is a big mission in the field.  Dr Nevel: Yeah, that makes total sense. And kind of leaning into this, you know, trying to differentiate between these different causes of late-life amnestic cognitive impairment. You know, I'll point out to the listeners today to please read your article, but in addition to reading your article, I'd like to note that there's a really nice table in your article, Table 6-1, where you kind of go through the different causes of amnestic cognitive impairment and the different features that better fit with diagnosis X, Y, or Z, because I think it's a really nice table to reference and really easy to look at and reference back to. But on that note, what is your typical approach when you're seeing a patient in clinic, have a new referral for an older patient presenting with a predominantly progressive amnestic-type features? Dr Ramanan: Excellent question. And this is one that I think has relevance not just in a subspecialty memory clinic, but to all the clinicians who help to diagnose and manage cognitive disorders, including in primary care and general neurology and others. One principle that I think it's helpful to keep in our minds is that in cognitive neurology, no one data point takes precedence over all the others. We have a variety of information that we can gather from history, from exam, from imaging, from fluid biomarkers. And really the fun, the challenge, the reward is in piercing together that information. It's almost like being a lawyer and compiling the evidence, having possibilities on your list and raising and lowering those possibilities to get as close to the truth as you can. So, for patients with a cognitive syndrome, I think the first plank is in defining that syndrome. As you mentioned, if I'm seeing someone with a progressive amnestic-predominant syndrome, I first want to make sure, are we talking about the same thing, the patient, the care partner, and I?  Can often be helpful to ask them for some examples of what they see, because sometimes what patients may report as memory troubles may in fact reflect cognitive difficult in other parts of our mental functioning. For example, executive functioning or naming of objects. And so helpful to clarify that in the history to get a sense of the intensity and the pace of change over time, and then to pair that with a good general neurologic exam and some type of standardized assessment of their cognitive functioning. At the Mayo Clinic, where partial to the short test of mental status. There are other ways to accomplish that, such as with an MMSE or a MoCA. If I understand that the syndrome is a progressive amnestic disorder, Alzheimer's disease is the most common cause of that presentation in older adults, it deserves to be on my differential diagnosis. But there might be some other features in the story that could raise or lower those mimics on my list. So, in patients who are, say, older than the age of seventy five, disorders like LATE or PART start to rise higher on the likelihood for me, in particular if I know that their clinical course has been more slow brewing, gradually evolving. And again, most degenerative disorders we expect to evolve not over days or weeks, but over many months to many years. But in comparison with Alzheimer's disease, patients with LATE or with PART would be expected to have a little more slow change where maybe year over year they or their care partners really aren't noticing big declines. Their daily function is relatively spare. There might not be as much involvement into other non-memory cognitive domains. So, these are some of the pieces of the story that can help to perhaps isolate those other non-AD disorders on the list as being more likely and then integrating, as a next level, diagnostic testing, which helps you to rule in and rule out or support those different causes. So, for example, with LATE there can be often out of proportion to the clinical picture, out of proportion to what you see on the rest of their imaging or other profiles, very predominant hippocampal and medial temporal volume loss. And so that can be a clue in the right setting that you may not be dealing with Alzheimer's disease or pure Alzheimer's disease, but that this other entity is there. So, in the big picture, I would say being systematic, recognizing that multiple data points being put together helps you get to that confident cause or etiology of the syndrome. And in particular, taking a step back and thinking about big picture factors like age and course to help you order those elements of the differential, whether AD or otherwise. Dr Nevel: Great, thanks. In your article, you talk about different imaging modalities that can be used, as you mentioned, you know, just another piece of the puzzle, if you will, to try and put together what may be going on with the patient, and recognizing that some of these imaging techniques are imaging is special imaging, not available in a lot of places.  You know, and maybe other diagnostic type tests that could be helpful in differentiating between these different disorders may not be available, you know, for the general neurologist practicing in the community. So, what do you suggest to the general neurologist maybe practicing somewhere where they don't have access to some of these ancillary tests that could assist with a diagnosis?  Dr Ramanan: Critical question. And here I think there's not likely to be one single answer. As with most things, awareness and recognition is a good place to start. So, some of those clues that I mentioned earlier about the clinical course, about the age, the- we're talking about clinical setting there. So, comfort with and understanding that the clinical setting can help you to be more confident about, for example, LATE or PART being present in contrast to AD. That's important information. It deserves to be part of the discussion. It doesn't necessarily need other tests to have value on its own. A second piece is that tests help, in some cases, to rule in and rule out causes for cognitive difficulty. As part of a standard cognitive evaluation, we would all be interested in getting some blood tests to look for thyroid dysfunction or vitamin deficiencies. Some type of structural head imaging to rule out big strokes, tumors, bleeds. Head CT can accomplish some of that perspective. It's ideal if a brain MRI can be obtained, but again, keeping in mind, what's the primary goal of that assessment? It's to assess structure. Occasionally you can get even deeper clues into a syndrome from the MRI. For example, that very profound hippocampal or medial temporal atrophy. So, increasing awareness amongst clinicians throughout our communities to be able to recognize that change and put it in the context of what they see in other brain regions that can be affected by Alzheimer's or related disorders. For example, the parietal regions can be helpful. And recall that MRI can also be helpful in assessing for chronic cerebrovascular disease changes. This is another mimic that shows up in that table that you mentioned. And so multiple purposes can be satisfied by single tests. Now, you're absolutely right that there are additional test modalities that, perhaps in a subspecialty clinic at an academic medical center, we're very used to relying on and finding great value on; for example, glucose PET scans or sometimes fluid biomarkers from the blood or from the spinal fluid. And these are not always as widely available throughout our communities. Part of the challenge for all of us as a field is therefore to take the expertise that we have gathered in more subspecialty settings and tertiary care settings and translate and disseminate that out into our communities where we need to take care of patients. That's part of the challenge. The other challenge is in continued tool and technological development. There's a lot of optimism in our field that the availability of blood-based biomarkers relevant for Alzheimer's disease may play a part in helping to address some of the disparities in resource and access to care. You can imagine that doing a blood test to give you some high-quality information, there are going to be less barriers to doing that in many settings compared to thinking about a lumbar puncture or a PET scan, both in terms of cost to the patient as well as infrastructure to the clinicians and the care team. So I'm optimistic about a lot of those changes. In the meantime, I think there are, through both clinical evaluation and some basic testing including structural head imaging, there are clues that can help navigate these possibilities. Dr Nevel: So, let's say you have your patient in clinic, you've done your evaluation, maybe gotten some ancillary testing, and you highly suspect either LATE or PART. How do you counsel those patients and their families? How do you manage those patients moving forward who you really suspect don't have, you know, some sort of co-pathology? Dr Ramanan: So, it's- I think it's helpful to remember when patients are coming to see us, either they or the people around them have noticed an issue. And very likely it's an issue that's been brewing for a little while. I think it can be very valuable, very helpful for patients to have answers. What's the cause for the issue? Once you have answers, even if sometimes those answers are not the most welcome things or the things that you'd be looking forward to, answers give you an opportunity to grab hold of what's going on, to define a game plan. So, understanding there is a degenerative disease there, it sheds light on why that individual had had memory symptoms over the years. And it gives them a general expectation that over time on an individualized basis, but generally expecting gradually over many months to many years, there may be some worsening in some of those symptoms helps them to plan and helps them to make the adaptations that are a-ok and great to make to just help you to do the things you want to do. As much as I can, I try to put the focus here closer to how we would view things like high blood pressure or high cholesterol. Those are also chronic issues that tend to be more common as we get older, tend to get more troublesome as we get older. The goal is, know what you're dealing with and take the combination of lifestyle modifications, adaptations in your day-to-day and maybe medications to keep them as mild and as slow-changing as possible. With something like LATE, we don't have specific medication therapies to help support cognitive functioning at this time. There's a lot of hope that with additional research we will have those therapies. But even so, I think it's an important moment to emphasize some of those good healthy lifestyle habits. Staying mentally, socially and physically active, getting a good night's sleep, eating a healthy, balanced diet, keeping good control of vascular risk factors, all of that is critical to keeping the brain healthy, keeping the degenerative disease as mild and slow-brewing as possible. And understanding what some of the symptoms to expect could be. So, with LATE the syndrome tends to be very memory-predominant. There may be some trouble with maybe naming of objects or perhaps recall of emotionally salient historical knowledge, world events, but you're not expecting, at least over the short to medium term, huge intervening on other cognitive functioning. And so that can be helpful for patients to understand. So, the hope is once you know what what you're dealing with, you understand that the disease can look different from person to person. Having a general map of what to expect and what you can do to keep it in check, I think, is the goal. Dr Nevel: I agree with you 100% that it really can be helpful even if we can't, quote unquote, fix it, that for people, family, the patient have a name for what they have and kind of have some sort of idea of what to expect in the future. And they may come in thinking that they have Alzheimer's or something like that. And then, so, to get that information that this is going to be a little different, we expect this to go a little bit differently then it would if you had a diagnosis of Alzheimer's, I can see how that would be really helpful for people.  Dr Ramanan: I completely agree. And here's another challenge for us in the field when most patients have heard about Alzheimer's disease and many have perhaps even heard of dementia with Lewy bodies or frontotemporal dementia, but may not have heard of things like LATE. And they're not always easy to go online or find books that talk about these things. Having a name for it and being able to pair that with patient-friendly information is really critical. I see our appointments where we're sharing those diagnosis and making initial game plans as an initial foray into that process.  Dr Nevel: Yeah, absolutely. What is the greatest inequity or disparity that you see in taking care of patients with progressive amnestic cognitive impairment? Dr Ramanan: Yeah, great question. I think two big things come to mind. The first, you hinted at very well earlier that there are disparities in access to care, access to diagnostic testing, access to specialists and expertise throughout our communities. If we want diagnostics and therapeutics to be broadly applicable, they do need to be broadly available. And that's a big challenge for us as a field to work to address those disparities. There's not going to be one single cause or contributor to those iniquities, but as a field, I'm heartened to see thought and investment into trying to better address those. Another big weakness, and this is not just limited to cognitive neurology, it's a challenge throughout neurology, is that too many of our research studies are lacking in diversity. And that impacts our biological and pathophysiological understanding of these disorders. It also impacts our counseling and management. Again, if we want a new drug treatment to be broadly applicable throughout all of the patients that we take care of, we need to have data which guides how we apply those treatments. And so again, I'm heartened. This is a big challenge. It's a long standing challenge. It will take deep and long standing committed efforts to reverse. But I'm heartened that there are efforts in the field to broaden clinical trial enrollment, broaden observational research enrollment, and again, broaden access to tools and expertise. As a neurologist, I got into this field because I want to help people, use my expertise and my training to help people. These are steps that we can take to make sure that that help is broadly applicable throughout everybody in our communities. Dr Nevel: Yeah, absolutely. So, kind of segueing from you mentioning research and how we can better include patients in research. What do you think the next breakthrough is going to be? What do you think the next big thing is going to be in these disorders? What do we still need to learn? Dr Ramanan: There's a lot. I think for LATE and PART, the development of specific biomarkers would be top of the agenda. Now, biomarkers are by their nature imperfect. Even with Alzheimer's disease, where in comparison, we know quite a lot. We have a variety of imaging and fluid biomarkers that we can use to support or rule out a diagnosis. There are nuances in how you interpret those biomarkers. Patients can have signs of amyloid plaques in their brain and have completely normal cognition. They may be at risk for developing cognitive trouble due to Alzheimer's disease in the future, but it's one piece of the puzzle. Patients can have the changes of Alzheimer's disease amyloid plaques and tau tangles in the brain. We can confirm that through biomarkers. But at the end of the day, their cognitive syndrome might be driven by something else. Maybe it's Lewy body disease, maybe it's LATE, maybe it's a combination of factors. So, integrating and interpreting those biomarkers is challenging. But I do think, again, from the standpoint of giving patients answers with a diagnosis, having those biomarkers is really critical to just kind of closing the loop. It will also be critical to have those biomarkers as we're assessing for treatment response. So, for example, patients who may have coexistent Alzheimer's disease and LATE, I don't think we know the answer fully as to how likely they are to benefit from, say, newer antiamyloid monoclonal antibodies for Alzheimer's disease in the setting of that second pathology. So, wouldn't it be great if, similar to an oncologic setting where you engage in a treatment and then you're tracking two or three or four plasma measures and you're tracking tumor size with imaging, if we had this multimodal ability to track neurodegenerative pathology through biomarkers? I think that'll be a critical next step. And so, filling out that for non-Alzheimer's diseases, including LATE and PART, I think is item number one on the agenda. Dr Nevel: Wonderful, thank you so much. I really appreciate you taking the time to chat with me today about your article. I really enjoyed our conversation, certainly learned a lot. Dr Ramanan: Thank you so much, Kait. Love talking with you. And again, it was an honor to write this article. I hope it's helpful to many out in the field who take care of patients with cognitive issues.  Dr Nevel: Yeah, I think it will be. So again, today I'm interviewing Dr Vijay Ramanan about his article that he wrote with Dr Jonathan Graff-Radford on LATE hippocampal sclerosis and primary age-related tauopathy, which appears in the most recent issue of Continuum on dementia. Be sure to check out Continuum audio episodes from this and other issues. And thank you, Vijay, and thank you to our listeners for joining us today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/AudioCME. Thank you for listening to Continuum Audio.

In this episode of The Jon Gordon Podcast, we welcome Dr. Gary Josephson, a distinguished pediatric otolaryngologist and accomplished author. Throughout our conversation, Gary shares invaluable insights from his 26-year career in medicine and his journey towards becoming a successful speaker and author. His book, "Ordinary to Extraordinary: Seven Principles for Life Success," encapsulates his wisdom and experience, offering practical guidance for anyone seeking a more fulfilling life.   Gary's approach to healthy living is holistic and deeply rooted in daily practice, bridging physical well-being with spiritual enrichment. He candidly discusses the challenges of maintaining an exercise routine and the importance of proper nutrition, sleep, and ongoing education. His emphasis on hydration, balanced diet, and sufficient rest is not just theoretical but practiced in his own life daily.   One of the most profound aspects of our discussion is Gary's emphasis on having a spiritual core. He speaks to the strength and connectedness he finds through his diverse religious experiences, aligning with my belief in the importance of nurturing the soul to maintain a positive attitude. We delve into the philosophy of the subconscious mind and how it relates to the soul, exploring how a robust spiritual foundation can anchor us in times of adversity.   Gary also opens up about his principles on benevolence and connectedness. He shares moving anecdotes, including how a friend utilized his writing skills to offer resume workshops, demonstrating the ripple effect of personal acts of kindness. His reflections on Maslow's hierarchy of needs and the aspiration towards self-transcendence will inspire you to think about personal growth in new, service-oriented ways.   We discuss the significance of relationships, with Gary underscoring the importance of choosing the right life partner and maintaining strong connections for enduring happiness. His financial management advice also offers practical tips for sustainable wealth, reinforcing the importance of planning and balancing needs and wants. Gary's commitment to lifelong learning and education shines through, as he encourages us to blend knowledge with wisdom. This episode is a treasure trove of motivational insights and practical advice aimed at helping you unlock extraordinary potential in your everyday life. Join us for an enlightening conversation that spans health, spirituality, education, relationships, and personal growth. Let Gary Josephson's journey and principles inspire you to elevate each day from ordinary to extraordinary.   About Gary, Dr. Gary Josephson is a surgeon, researcher, educator, innovator, and author.  His recently released self-help book “Ordinary to Extraordinary: Seven Principles for Life Success” was a top 5 title sales by publication date as noted by Morgan James Publishing.  Dr. Josephson is a pediatric otolaryngologist-head and neck surgeon, experienced healthcare executive, and has held academic rank of Professor at the Mayo Clinic College of Medicine and the University of South Florida College of Medicine. He has been named in “Jacksonville's Best Surgeons in the City” and listed in “Castle Connelly” and “Best Doctors in America”.  He was the medical correspondent for a local newspaper when he lived in Manhattan. His column included health and wellness tips and facts to improve well-being. On a personal note, Dr. Josephson enjoys nature, outdoor activities, and staying physically fit. His greatest passion is spending time with his wife, Patricia, a practicing pediatrician, and their two children, Samantha and Grayson.   Here are a few additional resources for you… Every week, I send out a free Positive Tip newsletter via email. It's advice for your life, work and team. You can sign up now here and catch up on past newsletters. Join me for my IN PERSON Day of Development! You'll learn proven strategies to develop confidence, improve your leadership and build a connected and committed team. You'll leave with an action plan to supercharge your growth and results. It's time to Create your Positive Advantage. Get details and sign up here. Do you feel called to do more? Would you like to impact more people as a leader, writer, speaker, coach and trainer? Get Jon Gordon Certified if you want to be mentored by me and my team to teach my proven frameworks principles, and programs for businesses, sports, education, healthcare!

In a special co-branded episode between Oncology On the Go hosted by CancerNetwork® and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Alexis K. Kuhn, PharmD, BCOP, spoke with Katie Bruce, PharmD, BCPPS, and Susie Long, PharmD, about the use of approved cell-based gene therapies for patients with sickle cell disease, beta thalassemia, adrenoleukodystrophy (ALD), and metachromatic leukodystrophy (MLD). These panelists shared the pharmacist's perspective on ensuring quality care with these ex vivo gene therapies across all treatment phases, including mobilization, conditioning, and infection prophylaxis. Kuhn is an ambulatory Pediatric Hematology/Oncology/BMT Pharmacist at the Mayo Clinic in Rochester, Minnesota, and an assistant professor of Pharmacy at the Mayo Clinic College of Medicine. Bruce is a pediatric clinical pharmacy specialist at the Sarah Cannon Pediatric Hematology/Oncology & Cellular Therapy program of Tristar Centennial Medical Center in Nashville, Tennessee. Long is a pediatric clinical pharmacist in the Blood and Marrow Team at the University of Minnesota Masonic Children's Hospital. Specifically, the panelists spoke about the use of agents like elivaldogene autotemcel (Skysona) and atidarsagene autotemcel (Lenmeldy), which are FDA-approved for ALD and MLD, respectively. They also discussed the use of exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia), which the FDA approved for treating patients 12 years and older with sickle cell disease in December 2023. The conversation broke down each stage of treatment, detailing optimal strategies for the cell manufacturing and storing processes as well as the management of toxicities like cytopenias. They also reviewed key considerations during the post-infusion period that may help maximize the quality of life for patients after they complete their therapy. “It has been so amazing to be able to be a part of gene therapy and gene editing,” Bruce stated regarding the potential long-term impacts of these treatments. “We have patients who are able to hold full-time jobs they never were able to have before. We have patients who are climbing mountains and backpacking through Europe, which would have never been an option before because their sickle cell disease would have prevented them from [doing] that…. It's not an easy process, and it has a lot of steps for the patient to go through, but the reward at the end of it all is worth it.” References 1. bluebird bio receives FDA accelerated approval for SKYSONA® gene therapy for early, active cerebral adrenoleukodystrophy (CALD). News release. bluebird bio, Inc. September 16, 2022. Accessed October 7, 2024.https://tinyurl.com/mp8crxes 2. FDA approves first gene therapy for children with metachomatic leukodystrophy. New release. FDA. March 18, 2024. Accessed October 7, 2024. https://tinyurl.com/mrh659yk 3. FDA approves first gene therapies to treat patients with sickle cell disease. News release. FDA. December 8, 2023. Accessed October 7, 2024. https://tinyurl.com/3zbdnf4c

In a special co-branded episode between Oncology On the Go hosted by CancerNetwork® and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Alexis K. Kuhn, PharmD, BCOP, spoke with Katie Bruce, PharmD, BCPPS, and Susie Long, PharmD, about the use of approved cell-based gene therapies for patients with sickle cell disease, beta thalassemia, adrenoleukodystrophy (ALD), and metachromatic leukodystrophy (MLD). These panelists shared the pharmacist's perspective on ensuring quality care with these ex vivo gene therapies across all treatment phases, including mobilization, conditioning, and infection prophylaxis. Kuhn is an ambulatory Pediatric Hematology/Oncology/BMT Pharmacist at the Mayo Clinic in Rochester, Minnesota, and an assistant professor of Pharmacy at the Mayo Clinic College of Medicine. Bruce is a pediatric clinical pharmacy specialist at the Sarah Cannon Pediatric Hematology/Oncology & Cellular Therapy program of Tristar Centennial Medical Center in Nashville, Tennessee. Long is a pediatric clinical pharmacist in the Blood and Marrow Team at the University of Minnesota Masonic Children's Hospital. Specifically, the panelists spoke about the use of agents like elivaldogene autotemcel (Skysona) and atidarsagene autotemcel (Lenmeldy), which are FDA-approved for ALD and MLD, respectively. They also discussed the use of exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia), which the FDA approved for treating patients 12 years and older with sickle cell disease in December 2023. The conversation broke down each stage of treatment, detailing optimal strategies for the cell manufacturing and storing processes as well as the management of toxicities like cytopenias. They also reviewed key considerations during the post-infusion period that may help maximize the quality of life for patients after they complete their therapy. “It has been so amazing to be able to be a part of gene therapy and gene editing,” Bruce stated regarding the potential long-term impacts of these treatments. “We have patients who are able to hold full-time jobs they never were able to have before. We have patients who are climbing mountains and backpacking through Europe, which would have never been an option before because their sickle cell disease would have prevented them from [doing] that…. It's not an easy process, and it has a lot of steps for the patient to go through, but the reward at the end of it all is worth it.” References bluebird bio receives FDA accelerated approval for SKYSONA® gene therapy for early, active cerebral adrenoleukodystrophy (CALD). News release. bluebird bio, Inc. September 16, 2022. Accessed October 7, 2024.  https://tinyurl.com/mp8crxes FDA approves first gene therapy for children with metachomatic leukodystrophy. New release. FDA. March 18, 2024. Accessed October 7, 2024. https://tinyurl.com/mrh659yk FDA approves first gene therapies to treat patients with sickle cell disease. News release. FDA. December 8, 2023. Accessed October 7, 2024. https://tinyurl.com/3zbdnf4c

In this episode of ASTCT Talks, host Dr. Andrés Gómez De León is joined by Dr. Nandita Khera and Dr. Alexandra Gomez Arteaga to explore the critical issue of disparities and barriers to care in graft-versus-host disease (GVHD). The discussion delves into the factors contributing to unequal access to hematopoietic cell transplantation, such as socioeconomic status, race, and ethnicity, both in the U.S. and globally. The guests highlight initiatives like the ACCESS Initiative by ASTCT and the National Marrow Donor Program, aimed at addressing these disparities through advocacy, awareness, and training for junior faculty. They also discuss the importance of caregiver support, clinical trial accessibility, and the broader impacts of GVHD on patients' lives. Tune in to gain valuable insights into ongoing efforts to promote equitable access to life-saving treatments. About Dr. Nandita Khera Nandita Khera is a Professor of Medicine in the Mayo Clinic College of Medicine and a Consultant in the Division of Hematology/ Oncology at Mayo Clinic Arizona. She treats patients with hematological malignancies and some solid tumors, especially those needing blood and marrow transplant/cell therapy (BMT/CT). Her research focuses on improving the delivery of care to patients with cancer including those undergoing BMT/CT to help them be better prepared for the psychosocial and financial consequences of the treatment. She has published several papers in outcomes, late effects, and quality of care in cancer patients and provides mentorship to trainees interested in projects in these areas. She has been a member and has held leadership positions at Mayo Clinic and in the various committees in organizations/ societies in hematology and BMT/CT.. She was the working committee co-chair for the Health Services and International Issues Working committee of CIBMTR from 2015 to 2020 and a member of BMT-CTN SOSS Late Effects committee in 2020. As the co-chair of Dissemination and Implementation committee at BMT CTN currently, she leads efforts in improving translation of evidence into practice in the field of BMT. She is the Director of Community or Clinical Practice at ASTCT. About Dr. Alexandra Gomez Arteaga Dr. Alexandra Gomez Arteaga is an Assistant Professor at Weill Cornell Medicine/NewYork-Presbyterian Hospital and directs the Allogeneic Bone Marrow Transplant Service and the Advanced Fellowship in Bone Marrow Transplantation. She earned her MD from Los Andes University, completed her residency at the University of Miami, her Hematology/Oncology fellowship at Weill Cornell, and her BMT advanced fellowship at Memorial Sloan Kettering Cancer Center. Dr. Gomez's research focuses on improving outcomes in allogeneic stem cell transplantation for leukemia and myeloid malignancies, with an emphasis on young adults and alternative donors. Her work also addresses the critical need to decrease disparities in access to transplantation for minority populations, a cause she champions across her clinical practice, research, and advocacy. She currently serves as the Co-Chair for the Junior Faculty Initiative within the ASTCT ACCESS Initiative. About Dr. Andrés Gómez De León Dr. Andrés Gómez De León (@GomezDLeonMD) is an Associate Professor at Universidad Autonoma de Nuevo Leon in Monterrey Mexico and an ASTCT Content Committee member with an interest in acute leukemias and transplant and cell therapies in low and middle income countries.

In this episode of SEE HEAR FEEL, host Christine speaks with Dr. Yemi Sokumbi, a dermatologist and dermatopathologist at Mayo Clinic in Jacksonville, Florida, who is also the head of medical business development. They discuss key takeaways for innovation in healthcare, including the importance of embracing failure, solving familiar problems, and cross-pollination across medical disciplines. Dr. Sokumbi shares insights from her journey, emphasizing the value of tenacity and perseverance in bringing novel ideas to market, and touches on the nuances of encouraging diversity in innovation, particularly among women.00:00 Introduction to Dr. Yemi Sokumbi01:47 Defining Innovation in Medicine02:34 Lessons in Innovation and Failure05:25 Applying Innovation Lessons to Parenting07:19 Gender and Innovation10:14 Challenges and Perseverance in Innovation12:53 Final Thoughts on InnovationDr. Olayemi (Yemi) Sokumbi, MD is a dermatologist and dermatopathologist who is currently working at Mayo Clinic in Jacksonville, Florida where she also serves as Medical Director for Business Development. Additionally, she is involved with medical student and resident education in addition to her clinical work. She completed dermatopathology fellowship in 2014 at UT Southwestern Medical Center and was chief resident in dermatology at the Mayo Clinic College of Medicine. She has won numerous awards, including a 2022 Dean's Recognition Diversity & Inclusion Award from the Mayo Clinic Alix School of Medicine, a 2018 Outstanding Medical Student Teacher Award from the Medical College of Wisconsin, and the 2013 Richard K. Winkelmann Excellence in Research Award. 

Parenting can be overwhelming when your child is struggling with an anxiety disorder or OCD—but it doesn't have to be. In this episode we interview Dr. Stephen Whitewide about his new book "Anxiety Coach" and ways in which parents can partner with their child or teen who is struggling with anxiety (in particular, avoidance). Dr. Whiteside teaches parents what anxiety is and how to recognize when it becomes a problem, explains why children need to face their fears to overcome them, and introduces readers to exposure therapy and its practical application. Stephen P. H. Whiteside, Ph.D. is a Board-Certified Clinical Psychologist, Professor of Psychology in the Mayo Clinic College of Medicine and Science, and Director of the Pediatric Anxiety Disorders Program at Mayo Clinic in Rochester, MN. His research focuses on improving access to evidence-based care for pediatric anxiety disorders and obsessive-compulsive disorder. To purchase "Anxiety Coach," you can visit https://www.amazon.com/Mayo-Clinic-Anxiety-Coach-Groundbreaking/dp/B0BQMJNXR3

Today's podcast episode is part of the “Voices” series and is brought to you by the Diversity, Equity & Inclusion Committee. Join Dr. Amanda North, Chief of Urology at Children's Hospital at Montefiore Einstein and AUA Data Committee Chair, and Dr. Kevin Koo, Associate Professor of Urology at Mayo Clinic College of Medicine and Science, as they discuss the 10-year anniversary of the census and statistics that are important for identifying where diversity is needed in urology. 

This is a very important conversation on failure, what it can mean (and what it should not mean), and how it can be liberating to lean into it. Dr. Olayemi (Yemi) Sokumbi, MD is a dermatologist and dermatopathologist who is currently working at Mayo Clinic in Jacksonville, Florida where she also serves as Medical Director for Business Development. Additionally, she is involved with medical student and resident education in addition to her clinical work. She completed dermatopathology fellowship in 2014 at UT Southwestern Medical Center and was chief resident in dermatology at the Mayo Clinic College of Medicine. She has won numerous awards, including a 2022 Dean's Recognition Diversity & Inclusion Award from the Mayo Clinic Alix School of Medicine, a 2018 Outsanding Medical Student Teacher Award from the Medical College of Wisconsin, and the 2013 Richard K. Winkelmann Excellence in Research Award. 

I think we all had dreams as teenagers (or younger selves) - do you remember what yours were? Are your dreams the same now? Do you remember who you were vs. who you are now? This part of my conversation with Dr. Yemi Sokumbi touches on questions like these - the dreams she had an immigrant teen from Nigeria, the pressure she used to put on herself due to stereotype threat, and how it has been important for her to separate her identity from what she does at work. Dr. Olayemi (Yemi) Sokumbi, MD is a dermatologist and dermatopathologist who is currently working at Mayo Clinic in Jacksonville, Florida where she also serves as Medical Director for Business Development. Additionally, she is involved with medical student and resident education in addition to her clinical work. She completed dermatopathology fellowship in 2014 at UT Southwestern Medical Center and was chief resident in dermatology at the Mayo Clinic College of Medicine. She has won numerous awards, including a 2022 Dean's Recognition Diversity & Inclusion Award from the Mayo Clinic Alix School of Medicine, a 2018 Outsanding Medical Student Teacher Award from the Medical College of Wisconsin, and the 2013 Richard K. Winkelmann Excellence in Research Award. 

Parenting can be really hard when your child is dealing with anxiety or OCD. Ever stayed up late worrying about them? It feels like a big, confusing maze, doesn't it? But don't worry, you're not alone. In today's episode of The OCD Whisperer Podcast,  we are thrilled to sit down with Dr. Stephen Whiteside, a renowned clinical psychologist and a beacon of hope for families grappling with childhood anxiety and OCD. During the conversation we talk about his book "Anxiety Coach" and his specialized approach to treating childhood anxiety and OCD. We explore the importance of exposure therapy, the role of parents in treatment, and the challenges of diagnosing OCD in children. Dr. Whiteside shares insights on the stigma surrounding OCD and the benefits of group therapy, while emphasizing privacy in group settings. He discusses the effectiveness of his parent coach exposure therapy, citing research and positive outcomes from the Mayo Clinic's intensive treatment program. Resources and support options are highlighted, including the Anxiety Coach at Mayo Clinic website, which offers educational tools and details about their five-day intensive program. The episode concludes with encouragement for those on their journey to overcoming OCD.   In This Episode [01:11] The Anxiety Coach Book [02:07] Differences in approach [04:13] Components of the approach [07:40] Content of the book [08:32] Identifying anxiety disorders [10:39] Signs in pediatric population [12:25] Challenges in diagnosing OCD [14:56] Therapist misinterpretation of OCD [16:00] Stigma and judgment [16:59] Benefits of group therapy [18:34] Outcomes of parent-coached exposures [21:14] Empowering families   Notable Quotes [02:11] "The main component of the treatment for anxiety or OCD is helping kids learn through their own experience that what they're afraid of is unlikely to happen, and they can handle feeling nervous, worried, or uncomfortable until those feelings go away."- Dr. Stephen Whiteside [03:08] "We think that all kids will be more successful if they have someone to help them at home, and parents want to know what to do to be helpful."- Dr. Stephen Whiteside [09:55] "When fears and worries are excessive to the point that they're making life hard, distressing the child, or getting in the way of the parents' life, that's the time we need to start working on it."- Dr. Stephen Whiteside [16:59] "It's like this happens often enough that somebody wrote it down in a book, so I am clearly not the only one."- Dr. Stephen Whiteside [18:34] "We have some pretty good answers to that, but a lot more research needs to be done in general around child mental health."- Dr. Stephen Whiteside [21:14] "It's obvious to me that parents can learn to do this, and kids and parents can learn to do this together."- Dr. Stephen Whiteside   Our Guest Dr. Stephen Whiteside is a Board Certified Licensed Clinical Psychologist and Associate Professor of Psychology at Mayo Clinic College of Medicine, directs the Child and Adolescent Anxiety Disorders Program. With extensive experience in treating child, adolescent, and adult anxiety disorders, he's received grants from the Obsessive-Compulsive Foundation for neuroimaging studies on OCD. Dr. Whiteside's research focuses on childhood anxiety and treatment efficacy, reflected in numerous publications and national presentations.   Resources & Links Kristina Orlova, LMFT https://www.instagram.com/ocdwhisperer/ https://www.youtube.com/c/OCDWhispererChannel https://www.korresults.com/ https://www.onlineocdacademy.com Dr. Stephen Whiteside https://www.mayoclinic.org/biographies/whiteside-stephen-p-ph-d-l-p/bio-20054748 Mentioned Book: Anxiety Coach: A Parent's Guide to Treating Childhood Anxiety and OCD Website: https://anxietycoach.mayoclinic.org/     **Disclaimer** Please note, while our host is a licensed marriage and family therapist specializing in OCD and anxiety disorders in the state of California, this podcast is for educational purposes only and should not be considered a substitute for therapy. Stay tuned for bi-weekly episodes filled with valuable insights and tips for managing OCD and anxiety. And remember, keep going in the meantime. See you in the next episode!

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD When it comes to irritable bowel syndrome (IBS), it's important to keep in mind that there are certain diagnoses clinicians can make to specifically treat the underlying problem that's causing the symptoms that suggest IBS. To learn more about these complex mimickers, join Dr. Peter Buch as he speaks with Dr. Michael Camilleri, Professor of Medicine at the Mayo Clinic College of Medicine and Science.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD When it comes to irritable bowel syndrome (IBS), it's important to keep in mind that there are certain diagnoses clinicians can make to specifically treat the underlying problem that's causing the symptoms that suggest IBS. To learn more about these complex mimickers, join Dr. Peter Buch as he speaks with Dr. Michael Camilleri, Professor of Medicine at the Mayo Clinic College of Medicine and Science.

Paul Krauss MA LPC and Stephen Whiteside PhD, LP speak about how parents and caregivers can learn to play an important role in helping decrease anxiety and OCD symptoms in children. Stephen Whiteside has authored a new book entitled "Anxiety Coach: A Parent's Guide to Treating Childhood Anxiety and OCD."  Dr. Whiteside's book gives parents and caregivers an entire outline of what constitutes clinical levels of anxiety and OCD and what is normal in childhood development. He then explains many different types of treatments that are available and especially the current research on exposure therapy. Through reading this book, parents and caregivers can not only locate the most appropriate care of their child, they can also learn to assist their child in gaining confidence and possibly lowering their symptoms as well. Stephen P. Whiteside, PhD, LP is a Board-Certified Clinical Psychologist, Professor of Psychology in the Mayo Clinic College of Medicine and Science, and Director of the Pediatric Anxiety Disorders Program at Mayo Clinic in Rochester, MN. He received a BA in Psychology from Northwestern University and Ph.D. in Clinical Psychology from the University of Kentucky before completing a pre-doctoral internship in Pediatric Psychology at the Geisinger Medical Center and a post-doctoral fellowship in Child and Family Medical Psychology at the Mayo Clinic. His research focuses on improving access to evidence-based care for pediatric anxiety disorders and obsessive-compulsive disorder through the development of effective and efficient treatments facilitated by technology. He has received research funding from the National Institutes of Health, the Agency for Healthcare Research and Quality, the International OCD Foundation, and the Mayo Clinic Center for Innovation. He has published over 80 scientific articles, co-authored the books Exposure Therapy for Child and Adolescent Anxiety and OCD, Exposure Therapy for Anxiety: Principles and Practice (2nd Ed), and Mayo Clinic Anxiety Coach: A Parent's Guide to Treating Childhood Anxiety and OCD. Get involved with the National Violence Prevention Hotline: 501(c)(3) Donate / Share with your network Write your congressperson / Sign the Petition Looking for excellent medical billing services? Check out Therapist Billing Services. A behavioral and mental health billing service developed by therapists for therapists. Preview an Online Video Course for the Parents of Young Adults (Parenting Issues) Paul Krauss MA LPC is the Clinical Director of Health for Life Counseling Grand Rapids, home of The Trauma-Informed Counseling Center of Grand Rapids. Paul is also a Private Practice Psychotherapist, an Approved EMDRIA Consultant , host of the Intentional Clinician podcast, Behavioral Health Consultant, Clinical Trainer, and Counseling Supervisor. Paul is now offering consulting for a few individuals and organizations. Paul is the creator of the National Violence Prevention Hotline (in progress) as well as the Intentional Clinician Training Program for Counselors. You can find Paul on Insight Timer. Paul has been quoted in the Washington Post, NBC News, Wired Magazine, and Counseling Today. Questions? Call the office at 616-200-4433.  If you are looking for EMDRIA consulting groups, Paul Krauss MA LPC is now hosting weekly online and in-person groups.  For details, click here. For general behavioral and mental health consulting for you or your organization. Follow Health for Life Counseling- Grand Rapids: Instagram   |   Facebook     |     Youtube  Original Music: ”Alright" from the forthcoming album Mystic by PAWL (Spotify) "Adrifting" from Casio Jazz by Kelley Stoltz (Bandcamp)

According to the National Academies of Sciences, Engineering, and Medicine (NASEM), nearly one-fourth of older adults aged 65 and older are at increased risk for loneliness and are considered to be socially isolated, with risk factors being attributed to hearing loss, losing family or friends, role changes such as retirement, living alone, and chronic disease. Geriatric syndromes — such as polypharmacy, falls, cognitive impairment like dementia and Alzheimer's disease, malnutrition, and incontinence — are clinical conditions and multifactorial impairments that are more commonly identified in older adults. Aging is definitely the normal trajectory of human life, but how can one age in a way that is considered healthy and with an optimal quality of life? How can an older adult look forward to the remaining years of life despite chronic illness? How can we help safeguard a geriatric's mental health despite feelings of abandonment, loneliness, and fear of being a burden to their caregiver/s?We are joined today by Dr. Christina Chen, a double board-certified geriatrician and internist at Mayo Clinic. She received her BS in Biology and Psychology from Michigan State University, MD from St George's University School Of Medicine, Internal Medicine residency at the University of Illinois College of Medicine, and Geriatric Medicine fellowship at the Mayo Clinic College of Medicine. She further achieved certificates in Acupuncture for Physicians from Helms Medical Institute and Executive Women in Leadership from Cornell University. Dr. Chen currently stands as an Attending Geriatrician and Assistant Professor of Medicine at Mayo Clinic Rochester, the Host of the Aging Forward Podcast, the Course Director of the Mayo Clinic Alix School of Medicine Senior Sages Curriculum. the Editor of the Mayo Clinic on Healthy Aging book, and the Medical Advisory Board of GrandPad, a customizable platform that delivers virtual care to seniors at home while keeping seniors connected to reduce social isolation and improve the telehealth experience.Livestream Air Date: August 17, 2023Follow Ying Ying (Christina) Chen, MD: InstagramFollow Friends of Franz Podcast: Website, Instagram, FacebookFollow Christian Franz Bulacan (Host): Instagram, YouTubeThankful to the season's brand partners: Covry, House of M Beauty, Nguyen Coffee Supply, V Coterie, Skin By Anthos, Halmi, By Dr Mom, LOUPN, Baisun Candle Co., RĒJINS, Twrl Milk Tea, 1587 Sneakers

On this episode of Hands in Motion, we are joined by Nora Barrett and Stephanie Kannas who are both hands therapists who are current Affiliate Directors on the board of the American Association for Hand Surgery. They share with us how therapists can become involved in AAHS and give us the inside scoop on the upcoming meeting that will be held in Hawaii in January 2025. Guest bio: Nora Barrett, OTR/L, CHT, WCCNora has been a practicing occupational therapist since 1998 and a Certified Hand Therapist since 2006. She spent her early career as an inpatient therapist at rehabilitation centers, acute care hospitals and burn units in Boston, MA and Washington, DC before focusing in outpatient hands in Washington, DC, Baltimore, MD and Bend, OR. Nora moved to Charlottesville, VA in 2021 and joined the Hand Therapy Team at the University of Virginia Physicians Group where she works in the Hand Center and in an outpatient hand therapy practice. She received her Wound Care Certification in 2020 and is an active member of the American Society of Hand Therapists (ASHT) and the American Association for Hand Surgery (AAHS). She lectures routinely in wound care, burn therapy, trauma and peripheral nerve injury for ASHT, AAHS and various universities across the country.Guest bio: Stephanie Kannas, OTD, OTR/L, CHTStephanie is the Director of the Occupational Therapy Fellowship Program, Coordinator of the Occupational Therapy Hand Fellowship Program and clinical lead occupational therapist in hand therapy at the Mayo Clinic in Rochester, MN. She is an assistant professor for the Mayo Clinic College of Medicine and Science. Stephanie serves on the AO North America Hand Education Committee and holds an Affiliate Member At Large position for the American Society of Hand Surgery. She received her baccalaureate degree in occupational therapy in 2000 from the University of St. Catherine in St. Paul, Minnesota. In 2016, she earned her post-professional doctoral degree in occupational therapy and successfully completed the hand therapy elective track from Rocky Mountain University of Health Professions in Provo, Utah. She is a Certified Hand Therapist. She has over 21 years of experience at the Mayo Clinic. The majority of her time has been focused on hand injuries varying from complex trauma cases while patients are hospitalized for outpatient therapy needs.

This “MOGcast” edition of the “Ask the Expert” podcast series is a collaborative episode titled, “MOGcast 2: Understanding Cortical Encephalitis.” Dr. Eoin Flanagan and Dr. Cristina Valencia Sanchez joined Julia Lefelar of The MOG Project and Dr. GG deFiebre of SRNA to discuss cortical encephalitis, its symptoms, and the connection to MOG antibody disease (MOGAD) [00:04:21]. Audience members asked about the distinction between ADEM and cerebral cortical encephalitis, their treatments, diagnostic methods, and long-term impacts [00:35:34]. Dr. Flanagan and Dr. Sanchez agreed that the preventive treatment approach remains similar regardless of the MOGAD phenotype [00:40:36]. The discussion touched on recent studies on the diagnostic utility of MOG antibody testing in cerebrospinal fluid, and ongoing research on treatments, including clinical trials for developing FDA-approved medications for MOGAD [00:43:05]. Dr. Flanagan and Dr. Sanchez addressed community questions on fulminant cortical involvement cases [00:50:00], the long-term effects of Rituximab treatment [00:51:23], anxiety attacks and mood swings in ADEM [00:53:34], and treatment decisions based on antibody levels [00:54:49]. Eoin Flanagan, MB, BCh is a Professor of Neurology and Consultant in the departments of Neurology and Laboratory Medicine and Pathology at the Mayo Clinic (Rochester, MN). He completed his medical school training at University College Dublin in Ireland in 2005. He did a medical residency in Ireland and then completed neurology residency, fellowships in neuroimmunology and a masters in clinical and translational science at Mayo Clinic (Rochester, MN). He works in the Autoimmune Neurology and Multiple Sclerosis Clinics and the Neuroimmunology Laboratory at the Mayo Clinic. His clinical expertise and research are focused on inflammatory myelopathies and their imaging patterns, myelin oligodendrocyte glycoprotein (MOG) antibody associated disorder, neuromyelitis optica spectrum disorders, autoimmune encephalitis, paraneoplastic neurologic disorders, and multiple sclerosis. He is principal investigator on an NIH RO1 grant studying MOG antibody associated disorder. Cristina Valencia Sanchez, MD, PhD is an Assistant Professor of Neurology and Senior Associate Consultant in the Department of Neurology at the Mayo Clinic (Phoenix, AZ). She completed her medical school training and PhD in Neuroscience at the Universidad Complutense de Madrid. She did a Neurology residency in the Hospital Universitario Clinico San Carlos and then completed Neurology residency and fellowships in ARZ Multiple Sclerosis and RST Autoimmune Neurology at the Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine, in Arizona and Minnesota. The research interests of Dr. Valencia Sanchez focus on autoimmune disorders involving the central nervous system. These include neuromyelitis optica spectrum disorders, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), autoimmune encephalitis, and paraneoplastic neurological syndromes. She is particularly interested in the neurological complications of immune checkpoint inhibitor cancer immunotherapy. The clinical trials that she leads at Mayo Clinic in Arizona are among the first studies that may lead to approval of new targeted therapies for MOGAD and autoimmune encephalitis. Additionally, Dr. Valencia Sanchez's clinical research allows for increased recognition of autoimmune neurological disorders. Also, her work is helping to avoid misdiagnosing autoimmune encephalitis in the clinical setting. Her research leads to earlier diagnosis and appropriate treatment to ultimately improve patient outcomes.

Our bones are constantly breaking down and remaking themselves. In fact, an adult human skeleton replaces itself every five to 10 years.As we get older, that creation of new bone can't keep up with the loss of old bone. Our bones get weaker and more brittle, a condition called osteoporosis, and that puts us at higher risk of breaking a hip, a rib or something else if we fall.But there's a lot we can do at all ages to build stronger bones. MPR News host Angela Davis talks with two doctors about how diet, exercise and medications can build our bone density and help prevent fractures as we age.Guests:  Dr. Jad Sfeir is an endocrinologist and gerontologist and an assistant professor at the Mayo Clinic College of Medicine and Science in Rochester. He specializes in osteoporosis and age-related decline in bone strength. He also sees patients with rare bone diseases. Dr. Suzanne Hecht is an associate professor with the Program in Sports Medicine at the University of Minnesota Medical School and a sports medicine physician with M Health Fairview. She's also a team physician for University of Minnesota Athletics and U.S. Figure Skating and is a member of the USA Gymnastics National Healthcare Referral Network.

Bio Stephen P. H. Whiteside, Ph.D. is a Board-Certified Clinical Psychologist, Professor of Psychology in the Mayo Clinic College of Medicine and Science, and Director of the Pediatric Anxiety Disorders Program at Mayo Clinic in Rochester, MN. He received a BA in Psychology from Northwestern University and Ph.D. in Clinical Psychology from the University of Kentucky before completing a pre-doctoral internship in Pediatric Psychology at the Geisinger Medical Center and a postdoctoral fellowship in Child and Family Medical Psychology at the Mayo Clinic. His research focuses on improving access to evidence-based care for pediatric anxiety disorders and obsessive-compulsive disorder through the development of effective and efficient treatments facilitated by technology. He has received research funding from the National Institutes of Health, the Agency for Healthcare Research and Quality, the International OCD Foundation, and the Mayo Clinic Center for Innovation. He has published over 80 scientific articles, co-authored the books Exposure Therapy for Child and Adolescent Anxiety and OCD, Exposure Therapy for Anxiety: Principles and Practice (2nd Ed), and Anxiety Coach: A Parent's Guide to Treating Childhood Anxiety and OCD. Sign up for 10% off of Shrink Rap Radio CE credits at the Zur Institute

In this episode, I'm joined by Dr. Stephen Whiteside, a Board-Certified Clinical Psychologist and Director of the Pediatric Anxiety Disorders Program at Mayo Clinic in Rochester, MN. We talk about.. How parent-coached exposure therapy differs from Cognitive Behavioral Therapy How anxiety disorders differ from everyday nerves and worries Who the best people are to help coach kids through their fears and worries Stephen P. H. Whiteside, Ph.D. is a Board-Certified Clinical Psychologist, Professor of Psychology in the Mayo Clinic College of Medicine and Science, and Director of the Pediatric Anxiety Disorders Program at Mayo Clinic in Rochester, MN. His research focuses on improving access to evidence-based care for pediatric anxiety disorders and obsessive-compulsive disorder through the development of effective and efficient treatments facilitated by technology. He has published over 80 scientific articles, co-authored the books Exposure Therapy for Child and Adolescent Anxiety and OCD, Exposure Therapy for Anxiety: Principles and Practice (2nd Ed), and Mayo Clinic Anxiety Coach: A Parent's Guide to Treating Childhood Anxiety and OCD. Anxiety Coach book purchasing link: https://www.amazon.com/Mayo-Clinic-Anxiety-Coach-Groundbreaking/dp/B0BQMJNXR3 Mayo Clinic Press website:  https://mcpress.mayoclinic.org/ Mayo Clinic Press Instagram:  https://www.instagram.com/mayoclinicpress/ Mayo Clinic Press Facebook:  https://www.facebook.com/mayoclinicpress Mayo Clinic Press LinkedIn:  https://www.linkedin.com/company/mayo-clinic-press/

Special Series Focus: DRP's: Emerging DRP Leaders in Medical Education Description In this episode we delve into the dynamic world of emerging leaders engaging with five remarkable professionals who are shaping the future of Disability Resource Professionals (DRPs) in medical education. Our conversation explored the essence of leadership, the qualities that define effective leaders in disability resources, and the personal journeys that have shaped our guests into the leaders they are today. This episode is a treasure trove of wisdom, and we are excited to share three key takeaways: 1. Leadership is a Journey of Continuous Growth and Adaptability Our guests shared their personal leadership paths, emphasizing that leadership isn't a static quality but a dynamic process of learning and evolving. They highlighted the importance of adaptability, critical thinking, and effective communication as cornerstones for navigating the ever-changing landscape of disability resources in health sciences. 2. The Power of Vulnerability and Authenticity in Leadership Throughout the episode, our guests underscored the significance of vulnerability and authenticity in building trust and fostering a supportive environment. Leaders who embrace their humanity and acknowledge their mistakes create a culture of openness and learning, which is essential for team growth and resilience, especially in challenging times. 3. Mentorship and Role Modeling Shape Aspiring Leaders The stories shared by our guests revealed the profound impact of mentorship and positive role modeling on their leadership development. Whether it was through formal training programs or organic relationships, the guidance and example set by seasoned leaders played a pivotal role in shaping the next generation of DRPs. This mentorship goes beyond professional development, touching on personal growth and ethical conduct. Don't forget to subscribe, like, share, and comment with your thoughts after listening or reading!  Host Lisa Meeks: The host of the podcast and mentor to all of the guests. Guests: We were joined by a diverse group of individuals, each bringing a wealth of experience and unique perspectives to the table: Matt Sullivan from Washington University in St. Louis, with over a decade of experience in disability resources and a key role in the DRP Academy. Kara James, the Disability Access Resource Specialist at the Mayo Clinic College of Medicine and Science, who has dedicated over 20 years to disability services in higher education. Emily Langham, the director of student disability services at Eastern Virginia Medical School, who has been a facilitator for the Disability Resource Professional Academy. Ellen Kaplan, the assistant director of SDS for the Johns Hopkins School of Medicine, with a background in special education and advocacy spanning over 30 years. Bill Eidtson, the assistant dean for academic advising at the Geisel School of Medicine at Dartmouth College, who has a rich history in faculty development and academic advising. Transcript Keywords: Disability Resource Professional, Disability, DRP, Accommodation, Leadership, Mentorship. Produced by: Lisa Meeks and Jacob Feeman Audio editor: Jacob Feeman Digital Media: Lisa Meeks

Stephen P. H. Whiteside, PhD is a clinical psychologist, Professor of Psychology in the Mayo Clinic College of Medicine and Science, and Director of the Pediatric Anxiety Disorders Prgram at the Mayo Clinic in Rochester, MN.  His new book will be out in April in which he  outlines parent-coached exposure therapy. Unlike other therapy experiences, where children meet alone with a therapist, Dr Whiteside focuses on teaching parents how to help children work on their anxiety or OCD at home. In this interview we talk about his approach to treating anxiety disorders and some of the challenges in treating all anxiety disorders. 

Co-Occurrence #4 - The Future is Now: How VR and AR are Revolutionizing Medical and Health Sciences Education (EP.27) With Ryan Kingsley, MPAS, P.A.-C. Virtual reality and Augmented Reality are among some of the most exciting technologies that are revolutionizing the innovation possibilities within our learning landscape today. These cutting edge technologies, VR and AR, along with rapidly changing and growing AI capabilities, are having transformative impacts on health science and medical education. In this episode, Mayo Clinic College of Medicine and Science Assistant Professor of Medical Education, Ryan Kingsley, MPAS, P.A.-C., shares his insights into using these technologies in education -drawing on the spirit of innovation, real life examples and visions for the future. This episode is the fourth installment of our limited series, "Co-Occurrence," featuring conversations exploring AI and related technologies as well as possible, probably and actual impacts on education. From discussions around what we know, what we hope for, and what is happening concretely today - this limited series will give you some things to ponder and actionable takeaways. Questions? Feedback? Ideas? Contact us at edufi@mayo.edu Audio Editor: Jaquan Leonard Additional Resources: Gan, W., Mok, TN., Chen, J. et al. Researching the application of virtual reality in medical education: one-year follow-up of a randomized trial. BMC Med Educ 23, 3 (2023). https://doi.org/10.1186/s12909-022-03992-6 Abhimanyu S. Ahuja, Bryce W. Polascik, Divyesh Doddapaneni, Eamonn S. Byrnes, Jayanth Sridhar, The digital metaverse: Applications in artificial intelligence, medical education, and integrative health, Integrative Medicine Research,Volume 12, Issue 1, 2023, 100917, ISSN 2213-4220, https://doi.org/10.1016/j.imr.2022.100917. Henry Matovu, Dewi Ayu Kencana Ungu, Mihye Won, Chin-Chung Tsai, David F. Treagust, Mauro Mocerino & Roy Tasker (2023) Immersive virtual reality for science learning: Design, implementation, and evaluation, Studies in Science Education, 59:2, 205-244, DOI: 10.1080/03057267.2022.2082680 Breining, G., By, Breining, G., & 28, Aug. (2018, August 28). Future or fad? virtual reality in medical education. AAMC. https://www.aamc.org/news/future-or-fad-virtual-reality-medical-education

Show notes: MAPA recently passed out awards to these three inspiring Minnesota PAs! Join us in celebrating their hard work and advocacy for our profession. Guests: Advocacy Award:Becky Ness, MPAS, PA-CNephrology Mayo Clinic Health System Instructor of Medicine, Mayo Clinic College of Medicine and Science mapa.advocate@gmail.com Preceptor of the Year Award: Steven Palmer, MPAS, PA-CEmergency Medicine and Urgent CareEssentia Health Brainerd Steven.Palmer@EssentiaHealth.org  PA of the Year Award: Kari Knodel-Vettel, MPAS, PA-CDepartment of Family Medicine Glencoe Regional Health  Host:Katarina Astrup, MSPAS, PA-CTelepsychiatryMinnesota Clinic for Health and Wellness 

In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with Allan Jaffe, M.D., a consultant in the Department of Laboratory Medicine and Pathology at Mayo Clinic, about cardiac troponins and checkpoint inhibitors. Dr. Jaffe is also the Wayne and Kathryn Preisel Professor of Cardiovascular Disease Research, professor of laboratory medicine and pathology, and professor of medicine in the Mayo Clinic College of Medicine and Science. Discussion includes:00:47 Introductory background on checkpoint inhibitors and cardiac troponins.15:12  Challenges with recognizing immune checkpoint inhibitor-associated myocarditis.19:28  Key takeaways for how laboratory professionals can support these patients.19:28 Considerations of questions that are top of mind when tackling these issues.

This DiepCJourney podcast will focus on breast imaging. The questions we will discuss are when to see a radiologist, types of imaging, and more specifics about each type. We will look at what the future looks like in medical imaging in breast cancer. I'm speaking to Dr. Randy Miles. Dr. Miles serves as the chief of breast imaging at Denver Health with oversite over the breast divisions clinical, research, and educational programs. He also serves as the associate director for research in the radiology department. He earned his medical degree from Mayo Clinic College of Medicine. Dr. Miles has achieved multiple awards throughout his career and served on medical missions in Haiti and the Dominican Republic. He completed his master's in public health degree from Harvard School of Public Health. He completed his diagnostic radiology residency training at the University of Illinois, Chicago where he served as chief resident. He went on to complete his breast imaging fellowship training at the University of Washington Medical Center, Seattle Cancer Care Alliance. Dr. Miles has been the recipient of numerous research grants and has published over fifty papers. He talks nationally on his work in artificial intelligence, health literacy, and breast cancer disparities. Join us as we share these topics that are of interest to those in the breast cancer community served at DiepCFoundation. Connect with Dr. Randy Miles on his social media accounts here: Twitter: Randy Miles, MD LinkedIn: Dr. Randy Miles  

Joan's guests today are: - Former Chicago mayoral candidate Paul Vallas - Tom Syron, subsidized organizer with SMART Local 265 on our Union Strong segment - Lisa H. Thurau, executive director of Strategies For Youth - Dante King, author and assistant professor at Mayo Clinic College of Medicine and Science - Eric Zorn, The Picayune Sentinel

If you're a pharmacist you are probably going to have thoughts about today's episode. I'm joined by pharmacist and Director of Pharmacy at Minnesota Oncology, Kirollos Hanna Pharm.D. I first met Kirollos at the end of 2020 in the context of an end-of-year report on oncology trends for the Association of Community Cancer Centers, that included a series of focus groups with ACCC members. I was deeply impressed by Kirollos's humanity, clarity, and pragmatism, and if you don't know Kirollos, I think you will be too.In this episode, we talk about the challenges and opportunities for pharmacists transitioning from clinical to non-clinical roles and explore the different roles pharmacists can take on in non-clinical settings, such as creating educational content or working in the pharmaceutical industry.Kirollos highlights the unique value that pharmacists bring to education and the importance of foundational knowledge in specialized areas like oncology pharmacy. But we also talk about the challenges pharmacists face every day and the evolving nature of the pharmacy field.Join us as we delve into the world of pharmacy and explore the possibilities for pharmacists as educators and their unique contribution as educators to continuing education in the health professions.Connect with KirollosKirollos is also Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine and Associate Editor for the Journal of the Advanced Practitioner in Oncology (JADPRO).Email: kirollos11@gmail.comAcronymsAdvanced Practitioner Society for Hematology and OncologyNational Comprehensive Cancer NetworkBoard Certified Oncology PharmacistsEducation VendorsMedscapeOncLive Pharmacy TimesSupport the show

Imagine embarking on a journey that not only helps you understand the unmet needs in cancer care, but also empowers you to play a more proactive role in your treatment. In today's podcast I share a conversation  with Dr. Mullangi from Memorial Sloan Kettering Cancer Center and a panel of physicians from Southwestern Medical Center and the Mayo Clinic College of Medicine .   They reveal the often overlooked aspects of cancer treatment from detection to diagnosis. I talk about a spotlight on the patient journey, clinical presentation and the broad spectrum of unmet needs in oncology. I add my views on emphasizing the importance of patients taking the reins of their care, asking pertinent questions and seeking psychological, social and spiritual support during diagnosis and treatment. Picture yourself in the midst of a candid discussion that not only speaks to your medical concerns, but also your human spirit. The second part the episode takes a transformative turn, touching upon the silver linings that emerge during challenging times. I delve into the significance of sharing our stories and experiences, the power of mutual upliftment, and the role of hope and dreams in our journey. I highlight the untapped potential of research to answer our most pressing questions about cancer care. This is a conversation that encourages you to be vulnerable yet resilient, to connect with others, and to draw strength amidst adversity. Whether you find support in an online community, a kind word from a stranger, or a quiet moment in the lap of nature, we invite you to join us in this enlightening discussion that empowers you to face your journey head-on, anchored in hope and knowledge.References:Okediji PT, Salako O, Fatiregun OO. Pattern and Predictors of Unmet Supportive Care Needs in Cancer Patients. Cureus. 2017 May 9;9(5):e1234. doi: 10.7759/cureus.1234. PMID: 28620565; PMCID: PMC5467772.Chiesi F, Bonacchi A, Primi C, Miccinesi G. Assessing unmet needs in patients with cancer: An investigation of differential item functioning of the Needs Evaluation Questionnaire across gender, age and phase of the disease. PLoS One. 2017 Jul 25;12(7):e0179765. doi: 10.1371/journal.pone.0179765. PMID: 28742867; PMCID: PMC5526559.Interested in the Breast Cancer Toolkit? This toolkit is designed to provide individuals with breast cancer and their families with the information and support they need."Living the life I want" was a phrase that I heard often while working with clients going through cancer, and so I created this podcast. I also saw that there is a gap in knowledge about cancer, lymphedema and how to manage recovery, so I created Fit after Breast Cancer.Thank you for your time and interest in this podcast! I invite you to leave a heartfelt review on whichever podcast platform you listen to. It does so much to bring exposure to the podcast and helps lift others up! Connect with me! Website: In the Rising Podcast Website Email: Bettina@intherising.com In the Rising Pinterest: In the Rising Facebook

Hosted by: Amanda Nickles Fader, MD, Associate Editor of Gynecologic Oncology Featuring: Gregg Nelson, MD, University of Calgary Sean Dowdy, MD, Mayo Clinic College of Medicine Olle Ljungqvist, MD, Örebro University Hospital Editor's Choice Papers: Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update

Editor's Choice Papers:  Enhanced recovery after surgery (ERAS reg) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update Editorial:  Gynecologic oncology surgery – Ready for the next step in ERASHosted by:Amanda Nickles Fader, MD, Associate Editor of Gynecologic Oncology Featuring: Gregg Nelson, MD, University of CalgarySean Dowdy, MD, Mayo Clinic College of MedicineOlle Ljungqvist, MD, Orebro University Hospital

In this final episode of our mini-series on value in academic medicine, Dr Ankur Kalra welcomes back Dr Nandan Anavekar, a Professor of Medicine at Mayo Clinic College of Medicine and consultant for both the Cardiovascular and Radiology Departments at Mayo Clinic, who also serves as the Program Director for the Adult Cardiovascular Diseases Fellowship program. In this inspiring conversation, Dr Anavekar and Dr Kalra discuss the education of postgraduate medical students and reflect on Dr Anavekar's role as a Program Director. Dr Anavekar shares his motivations and the moral framework he uses to approach his responsibility towards his students. The conversation then shifts towards the learning environment provided for medical students. Dr Anavekar contrasts the prevalent competitive culture and draws on Vedic philosophies to outline how we can strive for a student-centric culture that fosters a more collaborative environment and supports autonomous decision-making. Dr Anavekar asks listeners to look at medical education with fresh eyes by reframing what value means within this context. Finally, Dr Anavekar talks about the Global Cardiology University Project and his work on democratizing medicine on a global scale. How can we create a safe learning environment for medical students? What is Dr Anavekar's thoughts on the role of teachers and students in medical setting? What is Dr Anavekar's message to early-career faculty? Questions and comments can be sent to “podcast@radcliffe-group.com” and may be answered by Ankur in the next episode. Guest: @nandananavekar, host: @AnkurKalraMD and produced by: @RadcliffeCARDIO.

Audible Bleeding editor Wen Kawaji (@WenKawaji) is joined by MD/PhD student Rahul Ghosh (@ghoshrx), JVS editor-in-chief Dr. Thomas Forbes (@TL_Forbes), JVS Assistant Editor Dr. Paul Dimuzio (@pdimuziomd), and Associate Editor of the Journal of Vascular Surgery-Cases, Innovations and Techniques, Dr. Sherene Shalhub (@ShereneShalhub, @OHSUvascular), to discuss two great articles in the JVS family of journals regarding uncommon vascular conditions, including aberrant subclavian artery/Kommerell's diverticulum and vascular Ehlers-Danlos syndrome. This episode hosts Dr. Jonathan Bath, Dr. Peter Lawrence, and Dr. Bernardo Mendes, the authors of the following papers:   Articles: Contemporary Outcomes after Treatment of Aberrant Subclavian Artery and Kommerell's Diverticulum by Bath et al. Open repair of an infected abdominal aortic aneurysm in a patient with vascular Ehlers-Danlos syndrome by Mendes et al. Show Guests: Dr. Jonathan Bath (@MizzouVascular) -  Assistant Professor of Surgery and program director for vascular fellowship at the University of Missouri Dr. Peter Lawrence - Professor of surgery at @UCLAVascular, served as senior editor for both JVS and JVS-VL previously.  Dr. Benardo Mendes (@drbermendes) - Consultant in the Division of Vascular and Endovascular Surgery at Mayo Clinic, and is Associate Professor of Surgery at Mayo Clinic College of Medicine and Science.  Additional Notes: Vascular Low Frequency Disease Consortium Website  Visit here for a list of completed projects and publications. The VEDS Collaborative research study is still enrolling! Any patient interested in enrolling should reach out to VEDSColl@ohsu.edu and follow @VEDSCollabo and @OHSUvascular on Twitter. JVS-CIT will be dedicating a full virtual issue to patients with genetic aortopathy and arteriopathy. Resources for patients: https://thevedsmovement.org/ and https://www.ehlers-danlos.com/  Follow us @audiblebleeding Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.  

In the second part of our mini-series exploring the concept of value in academic medicine, Dr. Ankur Kalra once again engages in a compelling discussion with Dr. Nandan Anavekar. Dr Anavekar, a Professor of Medicine at Mayo Clinic College of Medicine and consultant for both the Cardiovascular and Radiology Departments at Mayo Clinic, also serves as the Program Director for the Adult Cardiovascular Diseases Fellowship program. In this stimulating and thought-provoking episode, Dr. Kalra and Dr. Anavekar delve into the topic of measuring success in medicine. Dr. Anavekar puts forward the argument that the ambiguous definition of academic achievement often results in damaging biases that have long-term repercussions on the medical field. As a program director, Dr. Anavekar believes that the number of published articles should not be the only or most crucial criterion for evaluating early-career faculty. He argues that it's important to also consider the "distance travelled" by candidates. Dr. Kalra raises pertinent questions about the practical implications of this approach, and Dr. Anavekar provides candid insights into his responsibilities. The conversation also sheds light on the "publish or perish" mentality and highlights the need to prioritize patient needs over the ideals of the experts treating them. Can we move beyond binary thinking when it comes to measuring success in medicine? How does Dr. Anavekar tackle research questions? What is the true essence of being "academic"? Questions and comments can be sent to “podcast@radcliffe-group.com” and may be answered by Ankur in the next episode. Guest: @nandananavekar, host: @AnkurKalraMD and produced by: @RadcliffeCARDIO.

In 2018, the loss of a friend to suicide compelled Dr Anavekar to embark on a profound journey of contemplative self-exploration. Now, he uses his experience to encourage and guide trainees to pose thought-provoking questions that challenge the status quo of the materialistic approach to medicine, ultimately leading to a more outcome-focused perspective. In this week's episode of Parallax, Dr Ankur Kalra sits down with guest Dr Nandan Anavekar, a Professor of Medicine at Mayo Clinic College of Medicine and Science. Dr Anavekar also serves as a consultant for both the Cardiovascular and Radiology Departments at Mayo Clinic and is the Program Director for the Adult Cardiovascular Diseases Fellowship program. In this episode, Dr Nandan Anavekar emphasizes the importance of inner exploration for physicians. He encourages questions such as "Who am I?" and "What is this world that I reside in?" to foster a deeper understanding of the human condition and patient care. Dr Anavekar also addresses the current cultural shift in cardiology toward measuring success by material possessions and procedures, advocating instead for a focus on outcomes. Dr Kalra probes further, asking how this philosophy can be applied in the Western, and particularly the US healthcare system. What is the Global Cardiology University project? How does Dr Anavekar encourage trainees to re-examine their role in patient care? What is his advice to our listeners?

     Dr. Rasmussen is a retired Air Force Medical Corps officer, Professor of Surgery, and Vice Chair of Education in the Department of Surgery at the Mayo Clinic College of Medicine and Science in Rochester, Minnesota.  He described his personal experiences and Military Medicine career in the previous episode (Part 1 of the interview). This episode focuses on the advances in vascular surgery and military surgery driven by the Wars in Iraq and Afghanistan. In this episode, you will hear about what happens when a casualty enters the surgical medical system and the goals and priorities of care after the point of injury. You will also hear about amazing advancements in treating injured blood vessels from a surgical standpoint and what lies ahead in combat casualty care while gaining an understanding of limb revascularization and the options surgeons face when dealing with critically injured combat casualties.  Dr. Rasmussen reviews some of the highlights of vascular surgery advances and innovations from World War I to present-day conflicts. Dr. Rasmussen spent nearly three decades in the military, with his initial vascular surgery career beginning in the National Capitol Region at Andrews AFB in 2001.  He received his medical degree from the Mayo Clinic College of Medicine and trained in General Surgery at Wilford Hall Air Force Medical Center. He returned to the Mayo Clinic for fellowship training in vascular surgery. He spent 20 years as a vascular surgeon, with his career spanning the wars in Iraq and Afghanistan.  Find out more and join Team WarDocs at www.wardocspodcast.com                 Honoring the Legacy and Preserving the History of Military Medicine The WarDocs Mission is to improve military and civilian healthcare and foster patriotism by honoring the legacy, preserving the oral history, and showcasing career opportunities, experiences, and achievements of military medicine. Listen to the “What We Are For” Episode 47. https://bit.ly/3r87Afm WarDocs- The Military Medicine Podcast is a Non-Profit, Tax-exempt-501(c)(3) Veteran Run Organization run by volunteers. All donations are tax-deductible, and 100% of donations go to honoring and preserving the history, experiences, successes, and lessons learned in military medicine. A tax receipt will be sent to you. WARDOCS documents the experiences, contributions, and innovations of all military medicine Services, ranks, and Corps who are affectionately called "Docs" as a sign of respect, trust, and confidence on and off the battlefield, demonstrating dedication to the medical care of fellow comrades in arms.           Follow Us on Social Media Twitter: @wardocspodcast Facebook: WarDocs Podcast Instagram: @wardocspodcast LinkedIn: WarDocs-The Military Medicine Podcast

     Dr. Rasmussen is a retired Air Force Medical Corps officer and is currently a Professor of Surgery and Vice Chair of Education in the Department of Surgery at the Mayo Clinic College of Medicine and Science in Rochester, Minnesota.     In this episode, you will hear about how Military Vascular Surgeons are trained and about their role in providing expert care on the battlefield.  Col Rasmussen had the opportunity to deploy multiple times across the globe and shares how Military Medicine prepares and provides care from the tip of the spear through the evacuation chain to medical centers in the United States.  Dr. Rasmussen explains how the work of he and his colleagues at the US Army Institute of Surgical Research and with the DoD Combat Casualty Care Research Program used data-driven research to improve how coalition forces care for wounded service members.  He also is an incredibly talented Vascular Surgeon, and he shares some insights and lessons he's learned from memorable cases over his distinguished career.    Dr. Rasmussen received his medical degree from the Mayo Clinic College of Medicine and trained in General Surgery at Wilford Hall Air Force Medical Center. He returned to the Mayo Clinic for fellowship training in vascular surgery. He has deployed multiple times to combat zones and has held numerous leadership positions in Military Medicine before retiring and returning to the Mayo Clinic as a Senior Associate Consultant in the Division of Vascular and Endovascular Surgery.          Find out more and join Team WarDocs at www.wardocspodcast.com Honoring the Legacy and Preserving the History of Military Medicine The WarDocs Mission is to improve military and civilian healthcare and foster patriotism by honoring the legacy, preserving the oral history, and showcasing career opportunities, experiences, and achievements of military medicine. Listen to the “What We Are For” Episode 47. https://bit.ly/3r87Afm WarDocs- The Military Medicine Podcast is a Non-Profit, Tax-exempt-501(c)(3) Veteran Run Organization run by volunteers. All donations are tax-deductible, and 100% of donations go to honoring and preserving the history, experiences, successes, and lessons learned in military medicine. A tax receipt will be sent to you. WARDOCS documents the experiences, contributions, and innovations of all military medicine Services, ranks, and Corps who are affectionately called "Docs" as a sign of respect, trust, and confidence on and off the battlefield, demonstrating dedication to the medical care of fellow comrades in arms.           Follow Us on Social Media Twitter: @wardocspodcast Facebook: WarDocs Podcast Instagram: @wardocspodcast LinkedIn: WarDocs-The Military Medicine Podcast

Talking with Dr. Jennifer Huberty today all things health, nutrition, childhood obesity, mindfulness, relaxation and much more. Jennifer is the Director of Science at Calm. She spent 18+ years as a research faculty, nine of those as an Associate Professor at Arizona State University in the College of Health Solutions. She holds three affiliations: Associate Professor and Research Scholar in the Department of Obstetrics and Gynecology at University of Arizona's College of Medicine in Tucson, Arizona; Adjunct Professor of Medicine at Mayo Clinic College of Medicine in Scottsdale, Arizona, and Adjunct Professor at Mays Cancer Center at UT Health San Antonio MD Anderson in San Antonio, Texas. During the episode we dig into her journey and passion for the health and fitness space, while touching on her work at Calm which has become the #1 app for mediation and sleep in the app store. She is educated as they come, but even more impressive than her credentials is her ability to walk the walk. Jennifer is a true practitioner of yoga, strength training, healthy eating and makes meditation a key piece of her life. I know you guys will dig this episode as much as I enjoyed recording it. You can stalk her at: https://jenhubertyphd.com/ ~ https://www.linkedin.com/in/jennifer-huberty-8b320066/ and her IG https://www.instagram.com/jenhuberty Reminder our 40 Days of Fitness is Open for Enrollment - https://www.jeremyscottfitness.com/40-days-of-fitness Thanks to our Sponsors: Athletic Greens www.athleticgreens.com/jeremyscott Free year supply of vitamin D3 with 5 free travel packs Sleeves Sold Separately - https://sleevessoldseparately.com/collections/jscott Code JSCOTT15 for 15% off all clothes & gear Dry Farms Wine - dryfarmwines.com/jeremyscottfitness Each new member will earn an extra bottle for just a penny with their first order of wine when they use this link. Jaylab Pro - https://jeremyscottfitness.jaylabpro.com/products.html